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 Chapter 1
Introduction
Based on: Current knowledge 
and future perspectives on acute 
hepatitis C
Sebastiaan J. Hullegie, Joop E. Arends, Bart J. A. Rijnders, 
William L. Irving, Dominique Salmon, Maria Prins, 
Annemarie M. Wensing, Paul Klenerman, Hakan Leblebicioglu, 
Christoph Boesecke, Jürgen K. Rockstroh 
and Andy I. M. Hoepelman 
Clinical Microbiology and Infection 2015;21(8):797.e9-797.e17.
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introduction 
The hepatitis C virus (HCV) is a single stranded RNA virus that is able to infect humans 
and chimpanzees. HCV is mainly transmitted by blood-blood contact and thereafter 
infects hepatocytes of the liver. When HCV has reached the liver, the immune system 
reacts on the presence of the virus, which results in inflammation. This immunological 
and inflammatory reaction can result in spontaneous clearance or can be insufficient 
leading to chronic persistence of the virus. 
The worldwide epidemic of HCV probably originated by the use of non-sterile medical 
equipment and blood transfusions between 1940 and 1960(1). The evolution of the 
virus in humans before that period is largely unknown(2). Between 1970 and 1989 
the disease was identified as non-A, non-B hepatitis and thereafter named HCV(3, 4). 
Currently, HCV is a widespread infectious disease throughout the world, with about 
170 million chronic carriers being theoretically able to transmit the virus(5).
HCV is a disease with potential severe complications like cirrhosis, hepatocellular 
carcinoma and hepatic decompensation(6). Besides liver related complications, other 
effects on different organs have been related to the presence of HCV like diabetes, 
cryoglobulinemia and kidney disease(7). However, most patients do not develop 
these complications and many are not aware that they are infected(8).
A recently acquired HCV infection is mostly asymptomatic, or at least stays unde-
tected, and leads to chronicity in 74% (95% CI 72% - 79%) of reported cases(9). 
Therefore, patients are mostly diagnosed in the chronic phase during general medical 
screening or when liver related complications occur. This results in a paucity of stud-
ies evaluating viral and immunologic characteristics of the first stage of disease, also 
called acute HCV. Furthermore, due to suboptimal study design (often retrospective 
cohorts) and small numbers of enrolled patients per study, many issues on acute HCV 
remain pending. The aim of the work presented in this thesis was to acquire further 
insight into the diagnostic methods and treatment in HIV infected patients with an 
acute HCV co-infection.
epidemiology
Three major populations at risk for new HCV infections can be identified, each with 
differing modes of transmission, occurring with different frequencies in different 
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parts of the world: injecting drug users, patients at risk of nosocomial infection and 
HIV positive men having sex with men (MSM)(5). 
Sharing of injecting equipment among drug users is a major risk factor for acute HCV 
and IDU accounts for most acute HCV infections worldwide. Currently, it is estimated 
that there are 0.75-1.0 million active IDU in Europe alone(10). Acute HCV incidence 
within this group varies between 2.7 and 66 per 100 person years of follow up (PYFU)
(11). This results in an anti-HCV prevalence of above 50% in Europe and around 67% 
worldwide(12, 13). A remarkable example of the ongoing epidemic in IDU outside 
Europe is within young adult IDU in the United States with reported incidences as 
high as 27 per 100 PYFU(14, 15). During the last decade this epidemic has expanded 
to rural areas and has been associated with increased prescription opiate use(16, 
17). In the IDU population a variety of interventions have been implemented that 
resulted in a reduced acute HCV incidence. Most implemented interventions are opi-
ate substitution and needle exchange programs of which high coverage of combined 
programs is associated with a reduction in acute HCV incidence(18, 19). However, 
HCV incidence within IDU does not seem to decline to the very low levels that have 
been observed for HIV(20). This difference might be attributable to the virological 
characteristics of the virus, as HCV is about 10 times more likely to be transmitted 
through a needle puncture than HIV(21). Furthermore, HCV transmission might also 
occur through sharing of drug use equipment other than needles such as tattooing 
or using snorting straws. 
Within health care systems of developed countries HCV transmission occurs infre-
quently. However, small transmission clusters are described occasionally. These 
outbreaks occur because of inadequate sterilization of medical devices or are driven 
by infected health care practitioners who spread the virus. For example, according to 
the national surveillance system in France, invasive medical procedures account for 
up to 25% of all acute HCV infections diagnosed(22). Additionally, in a recent review, 
13 outbreaks were described between 1995 and 2012 in Europe and the North 
America in which health care practitioners transmitted HCV to their patients(23). 
Accordingly, individual HCV transmission from patient to clinician was still reported 
in the Netherlands in 2013 and 2014(24). So, transmission of HCV still occurs in 
developed countries but not structurally.
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1In contrast, high rates of acute HCV infections within health care systems occur in 
developing countries. There are several developing countries that do not screen 
blood donors for HCV because of limited healthcare budget, leading to transmission 
of HCV. The most dramatic example is Egypt, in which the iatrogenic transmission 
of HCV during the era of parenteral anti-schistosomal therapy mass-treatment be-
tween 1960 and 1980 led to a nationwide epidemic. As a result, 10-20% of the 
total Egyptian population is currently infected, most of them with genotype 4. Inad-
equate sterilization of healthcare equipment and the high prevalence in the general 
population account for an ongoing spread of HCV in Egypt(25) resulting in an annual 
number of new HCV infections is estimated to be around 150,000(26). Intra-familial 
transmission (3%) and heterosexual transmission (0.07%) seem to be of limited 
importance(25, 27).
The third risk group for HCV infection is MSM in whom HCV is mainly a sexually 
transmitted disease. More specifically and for partially unknown reasons, this acute 
HCV epidemic has been limited largely to HIV positive MSM(28). In Europe, during the 
past decade incidence was rising from 0.08/100 PYFU up to 1.75/100 PYFU(29-33). 
Currently, the epidemic appears to be leveling off in the Netherlands(34). Outside 
Europe (the USA and Japan), HCV infections are still on the rise, with recent reported 
incidences between 0.21/100 PYFU and 2.49/100 PFYU(35, 36). The acute HCV rein-
fection rate is even higher with reported rates of 7.8 and 15.2 per 100 PYFU(37, 38). 
A supposed reason for this epidemic is the emergence of national and international 
networks of HIV positive men that serosort on HIV positivity and have unprotected 
sex(39). The occurrence of such networks may be explained by the successful HIV 
treatment, widespread internet use and low-budget travel possibilities(30, 40). 
Determinants for HCV transmission in this risk group are recreational drug use, 
injecting drugs, sharing of snorting straws, receptive fisting, receptive unprotected 
anal intercourse, ulcerative sexually transmitted infections such as syphilis, group 
sex and rectal trauma with bleeding(32, 41-44). There are also a number of potential 
mechanisms related to HIV that might result in enhanced infectivity and susceptibil-
ity to HCV, including increase HCV loads in serum and semen as well as defects in the 
gastrointestinal immune system(45).
Despite adequate surveillance systems, there is still a significant fraction (up to 45%) 
of acute HCV infections for which the mode of transmission cannot be identified. 
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Suggested explanations for these unknown transmissions include denial of risk fac-
tors, transmission by acupuncture, tattooing, piercing or shaving by barbers(25, 46).
diagnosis
Case definitions of acute HCV infection differ widely between epidemiologic, im-
munologic and intervention studies. Also, within these subgroups a wide range of 
criteria is used(47). 
Detection of seroconversion remains the most important diagnostic method of acute 
HCV infections(48). Detection of seroconversion and demonstration of genocon-
version by nuclear acid amplification assays, relies on the availability of a recent 
pre-diagnostic sample. Although sample storage is common practice within the HIV 
co-infected patients in tertiary-care centers in Europe, this is rarely done in other risk 
populations, who do not regularly visit outpatient clinics. Therefore, most acute HCV 
infections will remain undiagnosed. Alternatively, the combination of HCV antibody 
negativity and positive HCV RNA at a single time point may be indicative of an acute 
infection. However, in immunocompromised patients seroconversion takes time and 
remains absent in 2%-5% at one year after infection, making this combination less 
useful in HIV positive patients(49, 50). If a patient is already anti-HCV and HCV RNA 
positive at the time of first sampling, IgG avidity testing may give an estimation of 
infection duration(51). In case of reinfection, HCV genome amplification is the gold 
standard. Additionally, HCV antigen, IgG avidity and IgG titer measurements are 
promising alternatives(50, 52).
Although elevation of alanine transaminase (ALT) is still used in several definitions of 
acute HCV, cut-off points differ widely across studies from any value above the upper 
limit of normal to 20 times the upper limit of normal(47). Interestingly, the presence 
of normal ALT values in the acute phase of infection has been reported, in association 
with fluctuating viremia(53). Thus, excluding a diagnosis of acute HCV infection in a 
high-risk individual by relying on a normal ALT may not be appropriate.
Virology
Within the acute phase of a HCV infection, three patterns of HCV RNA kinetics can be 
identified. The first pattern is seen in spontaneous clearance, which occurs probably 
more frequently in HCV mono-infected than in HIV co-infected patients(9). This means 
that there is an initial rise in HCV RNA followed by a steady decline to undetectable 
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1levels of HCV RNA. Clinical observations show that this generally occurs within the 
first year after transmission, but may take up to two years (54). However, spontaneous 
clearance can occasionally also be observed in the chronic stage of disease when a 
patient’s immunity is restored or boosted by an infection with another hepatitis virus 
or when combined antiretroviral (cART) therapy is started(55-57). Second, a pattern 
of fluctuating viremia can be observed during an acute HCV infection. This pattern 
is defined by rapidly changing viral loads that can differ with a factor 10 to 100 with 
a few weeks(53, 58). This is an interesting virological pattern because currently we 
do not know whether it is preferable to observe the outcome during this phase or 
to start peginterferon (pegIFN) based treatment as early as possible to maximize 
treatment efficacy. The last pattern of HCV RNA kinetics during an acute HCV can 
be described as an early chronic pattern. In these patients a stable high viral load is 
seen. This may be observed because the fluctuating stage of disease is very short and 
therefore often missed, or because the immune system becomes exhausted shortly 
after infection(53).
Predicting clearance
The process leading to either spontaneous clearance or chronicity is dependent 
on specific viral and host characteristics. These determinants are heavily debated 
because they are based on studies in small numbers of patients or in different acute 
HCV cohorts: IDU, HIV co-infected, nosocomial infected or combined. In a recent 
multicenter study, patients with a genotype 1 infection had an adjusted hazards ratio 
(AHR) of 1.56 compared to other genotypes in favor of clearance(54). The chances 
for spontaneous clearance can also be partly explained the diversity in quasispe-
cies which can be a result of host, viral and external factors. Increased quasispecies 
heterogeneity equates with longer estimated duration of infection and higher serum 
HCV RNA levels. The heterogeneity in quasispecies can be partially explained by the 
route of transmission (IDU versus sexual)(59), immune exhaustion and the imperfect 
function of the viral RNA polymerase combined with a production of 10^12 virions a 
day(60). 
Important host protective factors that have been associated with spontaneous clear-
ance are: nonblack race (Odds Ratio(OR) 5.15), female gender (AHR 2.16) (with a pro-
tective effect of oestrogen) and host interferon lambda gene 28B (IL28) C/C genotype 
(AHR 2.26)(54, 61, 62). Differences in host IL28 polymorphisms seem to constitute 
one of the few genetic predictors of viral clearance, with CC being the most favorable 
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genotype, followed by CT and TT(63). The closely linked rs12979860 and rs8099917 
subtypes are associated with clearance, treatment effect and progression to cirrhosis 
in chronic HCV. For example within a study among 190 women, spontaneous clear-
ance was more common in patients with the C/C genotype (43/67; 64%) compared 
with C/T (22/90; 24%) or T/T (2/33; 6%) (P < .001)(64). The presence of hepatitis B 
antigens seems to be protective for chronicity (OR 2.91)(65). In contrast, infection 
with HIV is associated with progression to chronicity (OR 2.19)(61). However, when 
the immune status of a patient can be restored by combined antiretroviral therapy, 
the chance of spontaneous clearance seems to increase(66).
In the past, several models have been developed to prevent unnecessary peginter-
feron-based treatment for patients who would have cleared HCV spontaneously(54, 
67-70). These prediction algorithms rely on pathophysiological causative mecha-
nisms but also on clinical or biochemical symptoms like jaundice, bilirubin or the 
IP-10 level, which may be a reflection of well-functioning immune system. These 
algorithms reliably predict spontaneous cure rates but have not been prospectively 
validated. 
immunology
Cellular immune response
Mounting an effective T cell response is a key immunological element of spontane-
ous viral clearance(71). Specifically for acute HCV mono-infections, several studies 
have demonstrated that a broad and vigorous HCV-specific CD4+ and CD8+ T cell 
response is associated with clearance of the infection(72-75). Similar observations 
linking T cell responses to spontaneous viral clearance have been made in HIV-
infected patients with an acute HCV infection. However, comparisons between acute 
HCV mono-infected and HIV/ acute HCV co-infected patients have revealed impaired 
responses in the latter group, which may account for the observed reduced clearance 
rates in this patient group(75, 76).
The innate immune response also plays a role in the acute stage of the disease though 
its exact contribution is unclear. HCV RNA is sensed through either the helicase RIG-I, 
which forms a complex, or Toll-like receptors, ultimately leading to production of 
interferon alfa (IFN-alfa) and upregulation of interferon-stimulating genes (ISG)(77, 
78). Several HCV proteins have been shown to interact with this intracellular signal-
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1ing cascade, e.g. HCV protease, which cleaves the mitochondrial antiviral-signaling 
protein downstream of RIG-1(78, 79). Differences in production of IFN-alfa, both in 
plasma and in the liver, have been attributed to the observed differences in sponta-
neous viral clearance rates between acute HCV mono-infected and HIV/ acute HCV 
co-infected patients(80, 81). 
Humoral immune response
The role that antibodies play in the spontaneous clearance of acute HCV is less 
well understood(82). Early in vitro studies showed that highly specific neutralizing 
antibodies (NAs) against HCV envelope proteins E1 and E2 were frequently present, 
with the hypervariable region 1 (HVR1) in the E2 being an important target for NAs. 
However, technical limitations were encountered, e.g. use of pseudoparticle cell 
systems enabling only a limited number of viral genotypes together with the use 
of the general reference strain H77c. Despite the development of JFH-1 cell culture 
system, which accelerated NA research, how HCV evades neutralization still requires 
further elucidation. Partly, this can be explained by cell-to-cell spread via tight junc-
tions(83), partly because of the high specificity of these antibodies for variants that 
can subsequently mutate under selection pressure. Despite evasion of the immune 
system, there is clinical evidence for a significant role of NAs in protection against 
HCV. For example, from early hepatitis B immunoglobulin vaccination studies in 
liver transplant patients it became apparent that lower HCV recurrence rates were 
seen in those patients receiving hepatitis B immunoglobulin(84). Furthermore, in 
acute HCV infected patients, high NA titers corresponded with spontaneous viral 
clearance(85). Similar to the pattern of T cell responses, broadly NAs are associated 
with resolving infections(85). Such NAs may recognize conformational epitopes most 
often around the CD81 binding site, one of the co-receptors for HCV cell entry(86). 
Additionally, although it is a rare occurrence, NA binding to linear epitopes has been 
described(87), leading to the discovery of monoclonal antibodies such as AP33, with 
potent neutralization capacity(88). Taken together, the cellular and humoral immune 
system respond to the presence of a HCV infection. In most of the cases these re-
sponses are inadequate because they are interrupted by HCV itself or evaded by the 
high mutation frequency of HCV.
Vaccination
One question in the era of direct acting antivirals (DAAs) is whether we still need a 
vaccine. It could be reasonably argued that, on a population level, vaccination is the 
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most effective way of eradicating HCV. Moreover, on an individual level, adequate 
treatment gives no protection against reinfection(38). However, the correlates of 
immunity for HCV are still largely unknown hampering vaccine development(89). 
Based on the chimpanzee HCV model a limited number of vaccine candidates have 
advanced into human clinical testing with varying degrees of success(90). Different 
approaches have been tried; vaccines based on recombinant proteins or peptides, 
DNA, and viral vectors. Combining two of these, e.g. a viral vector with a protein, 
seems attractive, potentially providing both humoral and cellular immunity(91). For 
example, the combination of an adenoviral vector with a recombinant HCV E1E2 
protein was demonstrated to elicit a strong antibody and T cell response in mice 
and guinea pigs(92). A recent phase 1 human study showed that very high levels of 
CD4+ and CD8+ T cells can be induced using viral vectors based on rare adenovirus 
serotypes: currently, a phase 2 study using such vectors is underway to investigate 
the efficacy of this prime-boost T cell vaccine approach in an injecting drug using 
community in Baltimore(93).
treatment
Until recently, acute and chronic HCV infections were treated with subcutaneous IFN-
alfa and oral ribavirin. The pegylated form of interferon is preferably used because it 
can be administered once a week subcutaneously. Interferon is a signal protein that 
can also be produced by many human cells in reaction to many different pathogens, 
in particular after a viral infection. Interferon has a broad range of actions, which 
result in general activation of the immune system. When combined with ribavirin, a 
broad spectrum antiviral drug with a not-well understood mode of action, interferon 
is a moderately effective treatment for chronic HCV and is a very effective treatment 
for acute HCV(62). However, the use of pegylated-interferon (pegIFN) and ribavirin 
is associated with several substantial side-effects like influenza-like symptoms, 
cytopenia and depression.
Optimal timing of acute HCV therapy
In clinical practice, the optimal timing of the treatment of an acute hepatitis C 
infection is controversial. It remains unclear until what time point after infection 
the chances of spontaneous clearance continue to outweigh the high cure rates of 
pegIFN based treatment for an acute HCV infection. A model to predict efficacy of 
treatment in comparison with the chance of spontaneous clearance proposes to 
treat within the first 2 months or after 4 months if the moment of transmission is 
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1known(68). However, this model assumes a reliable transmission date, which is often 
not available. As a result, most physicians refrain from applying treatment during at 
least the first month after diagnosis to await spontaneous clearance. This is in line 
with the current European AIDS treatment network (NEAT) and European Aids Clini-
cal Society (EACS) guidelines recommending a 4-week period to observe a potential 
HCV RNA decline of at least 2-log, after which the chance of spontaneous clearance 
becomes substantially higher(94-96). Without this 2-log decline, treatment can be 
initiated. However, observations from a large international study of 632 participants 
with acute HCV mono-infection did not support this approach. Among patients with 
spontaneous clearance, 33% became HCV RNA negative later than 6 months after the 
estimated date of infection(54). These data suggest that refraining from therapy for a 
longer time also has clear advantages. As a result, current EASL and AASLD guidelines 
are inconclusive about the observation period(48, 97). In 130 mono-infected patients 
who were treated after a 12 week delay, similar sustained viral response (SVR) rates 
were found as in studies using a 4 week observation period (98). In contrast, data 
from the German HepNET III study on acute HCV mono-infection did not support a 12-
week delay in treatment after diagnosis, as this was associated with a lower SVR rate 
than immediate treatment (SVR, 54% versus 67%)(99). Since the difference in SVR 
rates was largely driven by the fact that more patients in the delayed treatment group 
were lost to follow up, the authors concluded, however, that delayed treatment could 
be as effective when protocol and treatment adherence can be ensured. Nowadays, 
in the DAA era with cure rates of 90% and higher, timing of treatment initiation for 
acute HCV infections remains debatable.
Rationale for treatment
Patients with acute HCV have historically been treated with shorter regimens, yield-
ing substantially higher SVR rates, than those longer regimens used in patients with 
chronic infection. At the moment, it is still unclear why there is an increased response 
to interferon during acute infections. It is hypothesized that the early disappearance 
of HCV antigens prevents exhaustion of the immune system(100). An alternate expla-
nation could be that early treatment prevents the development of stable quasispe-
cies strains that are able to evade the immune response. 
With new DAAs being licensed, the treatment of chronic HCV infection has become 
safe and very effective. Therefore, early treatment may have no advantage with 
respect to SVR rates. As a result, current AASLD guidelines advocate waiting until 
18 Chapter 1
infection becomes chronic and selecting treatment regimens without pegIFN(97). 
However, there are several reasons to treat in the acute phase, e.g. to reduce viral 
transmission or to treat symptomatic patients. In many countries, the most important 
reason for treating with pegIFN-based regimens during acute infection is the lack 
of insurance coverage of new DAAs in patients without an urgent medical need for 
HCV therapy. This is certainly not restricted to resource-limited settings. In several 
European countries, DAAs can only be used in patients with advanced fibrosis or 
cirrhosis. Even when DAAs can be used regardless of fibrosis grade, DAAs are not 
EMA nor FDA registered for the treatment of acute HCV, as their efficacy and safety in 
patients with acute HCV has not yet been studied. Therefore, despite its side effects, 
pegIFN-based treatment for acute HCV will remain the only available option in many 
countries for several years to come.  
Treatment regimen for acute HCV infection
Currently, pegIFN-alfa as monotherapy, or in combination with ribavirin (in patients 
with HIV co-infection), is still the only treatment that has been adequately studied 
in patients with acute HCV infection and is approved for this indication. In acute 
HCV mono-infected patients, cure rates between 71% and 94% have been reported 
with pegIFN-alfa monotherapy(101, 102). As the therapeutic mechanism for pegIFN-
alfa and standard IFN-alfa is similar, starting the treatment with high-dose standard 
interferon-alfa 2a or 2b is common in resource limited setting in which pegIFN-alfa is 
not available or more costly.
The wide variety of cure rates within the HIV co-infected population makes it dif-
ficult to interpret the effects of different treatments. Small, mostly underpowered, 
cohort studies with a variable genotype distribution have shown an average cure 
rate of 61%(standard deviation of 17)(95). Although its role remains controversial, 
ribavirin is often added to pegIFN-alfa in HIV co-infection resulting in higher SVR 
rates in general. Most physicians start with pegIFN-alfa and ribavirin, with tapering or 
discontinuation of ribavirin if adverse events occur(48, 95). However mono-therapy 
could be suitable in a subset of co-infected patients treated within the first weeks 
after diagnosis of acute HCV infection(103).
Duration of treatment
In most clinical studies and treatment guidelines, the duration of pegIFN-alfa therapy 
in HCV mono-infected patients has been 24 weeks. However, 12 weeks of therapy 
Introduction 19
1has also been successfully used in observational studies with cure rates of 72% and 
74%(104, 105). In a recent large randomized controlled trial no difference in response 
rates between 24 weeks of pegIFN-alfa and 12 weeks of pegIFN-alfa (with or without 
ribavirin) was observed(98). As this study concluded that the only predictor of SVR 
was a rapid viral response at week 4, it is remarkable that this decision rule is not 
integrated in current EASL guidance(48).
For HIV co-infected patients, the 2015 EACS acute HCV guideline suggests to base 
treatment duration on the week 4 HCV RNA load. If HCV RNA is undetectable at week 
4, treatment with pegIFN and ribavirin until week 24 is recommended and if not, 
treatment duration has to be expanded to week 48 (96).
DAAs in the treatment of acute HCV
Several new classes of DAAs have shown cure rates above 90% in patients with 
chronic HCV, for both HIV negative and HIV positive patients (106-108). These DAAs 
inhibit three separate parts of the HCV replication cycle instead of boosting the host 
immune system with pegIFN-alfa and ribavirin. First, NS3/4a inhibitors, inhibit the 
viral protease which is responsible for cleavage of the HCV polyprotein into four 
different proteins. Second, NS5a inhibitors inhibit the broad function of NS5a that 
partly promotes HCV transcription and has also a function in modulating the host 
cell environment in favor of the virus (109, 110). NS5b inhibitors are (non) nucleoside 
analogues and inhibit the HCV polymerase (111). The HCV polymerase is an essential 
subunit of the replication complex to multiply the HCV genome(112). Besides the 
high effectivity of these DAAs, very few side effects of different regimens have been 
reported. For the newest combinations, i.e. grazoprevir and elbasvir or sofosbuvir and 
velpatasvir, the number of clinical side effects in the intervention group were equal 
to the number in the placebo arm(113, 114). However, rare but serious side-effects 
can only be excluded after marketing approval and therefore phase 4 studies and 
post-marketing data have to be awaited.
For the treatment of acute HCV, only telaprevir, a first generation HCV protease 
inhibitor has been tested in a pilot study in 19 co-infected patients. It was given 
for only 12 weeks in combination with pegIFN-alfa and ribavirin and a promising 
84% SVR rate was seen(115). If these results can be confirmed by other ongoing 
study’s, the use of first generation protease inhibitors for the treatment of acute HCV 
could become an effective and attractive treatment strategy(116, 117). Currently, 
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figure 1: ACUTE HCV treatment and response prognosis
table 1: Current and future studies with direct acting antivirals in acute HCV
Study name Coordinator Therapy HCV 
genotype
Duration 
(weeks)
HIV status Number of 
patients
DAHHS2 EMC GZP+EBV 1+4 8 -/+ 80
REACT Kirby 
Institute
SOF/VEL All 6-12 -/+ 250
TARGET3D Kirby 
Institute
DSV+PTV/r+ OBV 1 8-24 -/+ 60
DARE-C2 Kirby 
Institute
SOF+RBV All 8-6 -/+ 20
SWIFT-C ACTG SOF+LDV All 8 + 50
SOL UKB SOF+LDV 1,4 6 + 26
Hep-Net 
Acute HCV
MHH SOF+LDV 1 6 - 20
HCV: hepatitis C virus; EMC: Erasmus Medical Center, The Netherlands; UKB: Universitätsklinikum Bonn, 
Germany; Kirby Institute, Australia; ACTG: Aids Clinical Trials Group, the United States of America; MHH: 
Medizinische Hochschule Hannover, Germany;  RBV: ribavirin, SOF: sofosbuvir, LDV: ledipasvir; GZP: 
grazoprevir; EBV: elbasvir; VEL: velpatasvir; DSV: dasabuvir; PTV/r: paritaprevir/ritonavir; OBV: ombitasvir
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1also interferon free DAA containing studies are being set up (table1)(118). However, 
so far, no DAA containing regimen has been extensively studied in patients with an 
acute HCV infection. Therefore, pegIFN based therapy is likely to remain part of the 
treatment armentarium for acute HCV during the next several years. DAAs will be 
added consecutively, with decreasing treatment duration as a result (figure 1).
conclusion 
The field of acute HCV remains complex because of limited research into prevention, 
adequate diagnosis, treatment initiation and treatment regimens. Despite all efforts, 
there is still no conclusive evidence for a decline in spread of the virus within major 
risk populations. Even with high incidence rates, the identification and inclusion of 
substantial numbers of individuals with acute HCV for trials with sufficient power 
remains challenging.
The availability of new DAAs will result in many more patients being cured. The high 
rates of adverse events and discontinuations of pegIFN-based therapy have led to 
delays in treatment initiation in acute infections, with possible resultant onward 
transmission of infection. DAAs will probably be also effective for the treatment of 
acute HCV infections but this has to be demonstrated by adequate studies. Because 
of the projected significant costs and, therefore, limited worldwide availability of 
DAAs, it remains to be seen whether more advanced treatment approaches will have 
a substantial effect on a population level. 
aims and outline of this thesis
The general aim of this thesis is to study different aspects of an acute HCV infection in 
HIV positive MSM. The primary aim is to study the effectivity and safety of boceprevir 
in addition to pegIFN and RBV for the treatment of acute HCV infections within the 
Dutch Acute HCV in HIV study (DAHHS). Subsequently, the DAHH-Study provided an 
unique opportunity to study the epidemiologic, clinical, immunologic and virologic 
characteristics of acute HCV infections among HIV positive MSM in the Netherlands.
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In Chapter 2, the epidemiology of acute HCV infections in the Netherlands is studied 
based on an incidence measurement during the DAHH-Study in 2014. Because an 
acute HCV infection is sometimes difficult to diagnose, the additional value of HCV 
antigen testing in the diagnosis of acute HCV is studied in Chapter 3.
The results of the DAHH-Study are presented in Chapter 4 and address the primary 
aim of this thesis. In Chapter 5 potential drug-drug interactions with boceprevir and 
rilpivirine, a component of cART, are studied.  
Because of the high effectivity combined with high costs of DAAs there is increased 
interest in the benefits and costs on a societal scale. The economic as well as the 
epidemiological effects of mass-treatment of all HCV co-infected MSM are studied 
in Chapter 6.
A major threat to the effectivity of DAAs could be the emergence of resistant HCV 
variants. In Chapter 7, the presence of resistance associated substitutions in the 
DAHHS cohort is studied to determine whether resistance for different DAAs plays a 
role in patients with infections acquired in 2013 and 2014.
The immunological profile of acute HCV infections is studied in the last part of this 
thesis. In Chapter 8, the frequency and functionality of mucosal-associated invariant 
T cells is evaluated between healthy volunteers, HIV-infected, chronic and acute HCV 
infected patients. In Chapter 9 the biomarker profile of acute HCV infected patients 
is studied during their first and consecutive HCV infections.
In Chapter 10, the outcomes of this thesis are discussed and summarized. For laymen, 
a Dutch summary is provided in Chapter 11.
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abstr act
Within the Dutch Acute HCV in HIV Study, a surveillance system was initiated to es-
timate the incidence of hepatitis C virus infections in 2014. Following the Dutch HIV 
treatment guidelines, HIV-positive men having sex with men (MSM) in 19 participat-
ing centers were screened. Ninety-nine acute HCV infections were reported, which 
resulted in a mean incidence of 11 per 1000 patient-years of follow-up. Unfortunately, 
the HCV epidemic among Dutch HIV-positive MSM is not coming to a halt. 
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introduction
Acute hepatitis C virus (HCV) infections remain a major problem throughout the world 
within the populations of injecting drug users and patients undergoing non-sterile 
medical procedures. From 2001 the first reports on sexually transmitted acute HCV 
among men having sex with men (MSM) appeared(119). Although acute HCV can be 
successfully treated with interferon-based therapy in the majority of patients, this 
new epidemic has now become endemic in HIV-positive MSM(34). As acute HCV is of-
ten a clinically silent disease(120), the exact incidence can only be reliably measured 
when an active surveillance policy is followed. 
methods
To measure the incidence of acute HCV in HIV-positive MSM across the Nether-
lands, a surveillance system was initiated within the Dutch Acute HCV in HIV study 
(DAHHS). The DAHHS is a study on the efficacy of 12 weeks’ therapy with boceprevir, 
peginterferon and ribavirin for the treatment of acute HCV genotype 1 infections in 
HIV-infected patients(117). All 27 Dutch HIV centers were invited to report all acute 
HCV infections to the study coordinator and report characteristics of patients anony-
mously. Only patients who had not opted out for anonymous data registration in the 
Dutch ATHENA cohort were included(121). Participation of a center was confirmed if at 
least one acute HCV patient had been reported or a statement of ‘ absence of acute 
HCV diagnosis in 2014’ was sent to the study coordinator. 
According to the guidelines within the Dutch HIV care system, all HIV-positive MSM 
are screened for hepatitis using an alanine aminotransferase (ALT) measurement at 
least twice a year. When a rise in ALT above reference value is observed, the treating 
physician decides whether or not to test for HCV RNA. At the physician’s discretion, 
patients are also tested for HCV RNA when they report a HCV exposure or present 
with another sexually transmitted disease. Within this study an acute HCV infection 
was defined as a first positive HCV RNA measured in 2014, preceded by a negative 
HCV RNA or HCV immunoglobulin (Ig) G serology within one year before HCV RNA 
positivity. When a stored plasma sample from within the previous 12 months was not 
available to document the absence of HCV, a normal ALT preceding the first positive 
HCV RNA test together with a documented negative HCV IgG test at any time in the 
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past was used to exclude a chronic HCV infection. In patients without historical HCV 
test available to exclude chronic HCV, the combination of a positive HCV PCR with a 
negative HCV IgG finding was used to diagnose an acute HCV infection. The incidence 
rate was calculated using data from the Dutch Stichting HIV Monitoring (HIV Monitor-
ing Foundation, SHM) (121), which provides detailed information about the number 
of HIV-positive MSM in care in the different treatment centers in the Netherlands.
results
From January 1, 2014 until January 1, 2015 a total number of 99 acute HCV diagnoses 
were reported (table 1). Seventy-eight per cent of the acute HCV diagnoses were 
based on retesting of stored plasma to prove the absence of HCV RNA. Altogether, 
19 of the 27 HIV treatment centers participated, and at the end of 2014 at total of 
9487 HIV-positive MSM were in care in these 19 centers. To determine the number 
of person-years at risk in 2014, the number of MSM in care in the study centers was 
adjusted for the proportion of MSM already known to be chronically infected with 
HCV (4.8%) and for the increase in the number of HIV-positive MSM in care during 
table 1. Characteristics at the time of acute HCV diagnosis
N Median/% IQR Unit
Male 99 100%
Age 99 43 36-48 years
CD4 95 0.61 0.43-0.82 E9/l
cART yes 90 90%
no 5 5%
unknown 4 5%
HCV genotype 1 78 79%
2 2 2%
3 0 0%
4 18 18%
unknown 1 1%
Subtype within gen 1 a 74 95%
b 4 5%
Reinfection no 74 75%
yes 25 25%
ALT at diagnosis 91 191 93-520 U/L
HCV RNA at diagnosis 97 601 74-4925 E3 IU/ml
cART: combination antiretroviral therapy, HCV: hepatitis C virus, ALT: alanine amino-transferase, IQR: 
interquartile rage
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2014 (n=384)(121). The number of HCV RNA-negative, HIV-positive MSM at risk for 
acute HCV between January 1, 2014 and January 1, 2015 was therefore estimated 
at 8849 person-years. Using the 99 acute HCV infections, a mean incidence rate of 
11 per 1000 person-years of follow-up (PYFU) (95% confidence interval 9-14) was 
calculated. 
Spontaneous resolution was observed in 12% of the patients, 36% were treated 
with 12-weeks’ therapy with boceprevir, peginterferon-alfa and ribavirin (DAHHS 
protocol) and 20% were treated with another combination (mostly 24 weeks’ therapy 
with peginterferon with ribavirin). Thirty-one per cent of the patients did not initiate 
treatment. 
discussion
The calculated incidence of 11 per 1000 PYFU is a reliable representation of the 
Dutch acute HCV epidemic within HIV-positive MSM, as we included a population 
that represents 86% of all HIV-positive MSM in care in the Netherlands. Hence, it 
is clear that the acute HCV epidemic is no longer limited to a few large cities but 
has become a nationwide problem (median incidence per center 8.7/1000 PYFU, 
interquartile range 4,7-12). The number of genotype 1 infections, at 79%, is higher 
than previously reported (48-67%) and may indicate a genotype shift(34, 122, 123).
The incidence rate we found is comparable with international data from the United 
States (16/1000 PYFU) and Japan (20/1000 PFY) but not with incidence rates from 
Taiwan (4.9/1000 PYFU) and Switzerland (41/1000 PYFU) (32, 36, 122, 124). However, 
the incidence rate we found should be seen as a minimum incidence. Cases could 
have been missed because different ALT cutoff points were used in participating 
centers, as the exact threshold was not predefined and a diagnosed case can always 
remain unreported. Additionally, 10% (9/91) of the patients with a first positive HCV 
RNA did not present with a raised ALT above 44 U/L. This illustrates that a small but 
unknown number of additional acute HCV cases may remain undiagnosed. In our 
study the percentage of patients with a normal ALT at the time of the first positive 
HCV RNA was relatively low, in comparison to the 24% published by Thomson and 
colleagues(49). This may be explained by the fact that in Thomson’s study the date 
of the first ALT measurement was done earlier, at only 96 days after the date of the 
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last negative HCV RNA test. Interestingly, we observed that patients who cleared 
the infection spontaneously had a higher ALT than those who did not (ALT 1249 U/l 
versus 348 U/l, p=0.02).
It is clear that HCV infections continue to be a significant problem within HIV-positive 
MSM across the Netherlands as long as a significant proportion of HCV infections 
remains untreated. Fortunately, in the Dutch setting prompt identification seems 
possible. This well-defined population of HIV-positive MSM at risk may be an ideal 
population in which eradication strategies can be tested or implemented. Unfor-
tunately, the efficacy of the interferon-free therapies has never been investigated 
in the context of acute HCV. Therefore these therapies are not registered for the 
treatment of acute HCV. Furthermore, given the high costs of interferon-free HCV 
therapies, in the Netherlands, as well as in many other European countries they are 
only reimbursed for patients with Metavir F3 fibrosis or cirrhosis. Given the risk of 
ongoing HCV transmission if patients remain untreated, a restrictive reimbursement 
policy may be an expensive long-term strategy. Studies on the cost-effectivity of 
early HCV therapy that also take into account the benefits of a reduced risk of sexual 
HCV transmission are therefore needed.
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abstr act
Introduction
Acute hepatitis C virus infections (HCV) are prevalent among HIV positive men having 
sex with men and generally treated with peginterferon-alfa (pegIFN) and ribavirin 
(RBV) during 24 weeks. The addition of a protease inhibitor could shorten therapy 
without loss of efficacy.
Methods
We performed an open-label, single arm study to investigate the efficacy and safety 
of a 12-week course of boceprevir, pegIFN and RBV for acute HCV genotype 1 infec-
tions in 10 Dutch HIV treatment centers. Primary endpoint of the study was achieve-
ment of sustained virological response rate at week 12 (SVR12) in patients reaching 
a rapid viral response at week 4 (RVR4) and SVR12 in the intent to treat (ITT) entire 
study population was the most relevant secondary endpoint.
Results
One hundred twenty-seven acute HCV patients were screened in 16 months, of which 
65 acute HCV genotype 1 patients were included. After spontaneous clearance in six 
patients and withdrawal before treatment initiation in two, 57 started therapy within 
26 weeks after infection. RVR4 rate was 72%. SVR12 rate was 100% in the RVR4 
group. SVR12 rate in the ITT group was 86% and comparable to the SVR12 rate of 
84% in 73 historical controls treated for 24 weeks with pegIFN and RBV in the same 
study centers. 
Conclusion
With the addition of boceprevir to pegIFN and RBV, treatment duration of acute HCV 
genotype 1 can be reduced to 12 weeks without loss of efficacy. Given the high drug 
costs and limited availability of interferon-free regimens, boceprevir, pegIFN and RBV 
can be considered a valid treatment option for acute HCV. 
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introduction
During the last decade hepatitis C has emerged into a sexually transmitted disease 
within HIV positive men having sex with men (MSM). Incidence rates of hepatitis C 
virus (HCV) infections are estimated to be around 12/1000 person-years and the 
large majority of infections are with genotype 1 and 4(34). Acute HCV infections are 
generally defined as the period of infection in which the immune system attempts to 
eradicate the virus. This may lead to viral clearance but more often results in chronic 
disease(9, 126). An acute HCV infection in HCV mono-infected patients is treated with 
pegylated interferon-alfa (pegIFN) for 12 or 24 weeks, resulting in sustained virologi-
cal response (SVR) rates of about 54-98%(98, 101, 133-135). In HCV/HIV coinfected 
patients it is believed that the addition of ribavirin (RBV) is necessary to achieve 
comparable SVR rates with 24 weeks of therapy(95, 136). Recently, the addition of 
a direct-acting antiviral agent (DAA) to pegIFN and RBV increased cure rates both in 
chronic HCV mono- and HIV/HCV coinfected patients(137, 138). Also for acute HCV 
this was first demonstrated by Fierer and colleagues in a pilot study with 12 weeks 
telaprevir, pegIFN and RBV, which showed a cure rate of 84%(115). Thus, DAAs could 
also become a valuable addition in the treatment of acute HCV. Because HCV is a 
sexually transmitted disease in MSM, early treatment is crucial if one of the goals of 
treatment is the prevention of transmission. However, due to the very high drug costs, 
the availability of the recently approved pegIFN-free regimens for the treatment of 
chronic HCV is currently limited to patients with severe liver fibrosis or cirrhosis in 
most countries. Therefore, in patients with acute HCV, waiting until the infection has 
become chronic is not (yet) an option if treatment as prevention is aimed for. In the 
Dutch Acute HCV in HIV Study (DAHHS), our hypothesis was that addition of a prote-
ase inhibitor could shorten therapy duration without loss of efficacy. Therefore, we 
performed a single arm open-label study of a 12-week course with boceprevir, pegIFN 
and RBV in HIV coinfected patients with an acute HCV genotype 1.
methods
This investigator-initiated study was designed as a single arm, open-label multicenter 
intervention trial in 10 HIV treatment centers in the Netherlands. Other (non-study) 
Dutch HIV treatment centers were able to refer their patients to one of these study 
centers for treatment. We included adult, HIV-infected patients, who had to be on 
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combination anti-retroviral therapy (cART) at the start of HCV treatment. Patients that 
were included had to start treatment within 26 weeks after the assumed date of infec-
tion and had to be infected with HCV genotype 1 with a minimum viral load of 1000 
IU/ml at screening. Patients were excluded if they presented with a non-genotype 1 
infection, were unable to switch to a cART regimen consisting of nucleoside/tide re-
verse transcriptase inhibitors and raltegravir or rilpivirine, had a hepatitis B infection 
complicated by liver fibrosis (METAVIR>F1), had low platelets (<100E9/L), reduced 
kidney function (clearance <50 mL/min) or neutrocytopenia (<0.75E9/L). All patients 
provided written informed consent. The study was done according to Good Clinical 
Practice guidelines in accordance to the declaration of Helsinki and was approved 
by the ethics committee of the Erasmus Medical Center (ClinicalTrials.gov, number 
NCT01912495).
In the participating hospitals, HIV-positive patients were tested for HCV RNA if 
they presented with an alanine aminotransferase (ALT) rise above the upper limit of 
normal. ALT measurements were performed at least twice a year during regular HIV 
monitoring visits or more often at the discretion of the treating physician.
If a patient had detectable HCV RNA (CAP/CTM, V2, Roche diagnostics or Abbott 
Realtime M2000) genotyping was performed and the most recent stored plasma 
sample from previous visits to the outpatient clinic (up to one year before diagnosis) 
was tested for HCV RNA to determine whether infection was recent(49, 136). If no 
historical sample was available, the most recent (up to one year before diagnosis) 
negative HCV IgG test or ALT level below the upper limit of normal was used to ex-
clude chronicity. 
Genotype 1 infected patients with no 2-log HCV RNA drop four weeks after diagnosis 
had to initiate therapy within 26 weeks after the presumed date of infection (mid-
point between first positive HCV RNA and last negative laboratory test). If patients 
had a 2-log drop in HCV RNA one month after diagnosis, a consecutive HCV RNA 
measurement was performed 2 months after diagnosis(139). If there was no further 
significant decrease in HCV RNA at that time, treatment was initiated. 
Treatment consisted out of boceprevir (BOC) 800 mg thrice daily, weight based pe-
gIFN alfa-2b (1.5 μg/kg/week) and weight based RBV (<65 kg: 400 mg twice-, 65–80 
kg: 400 mg once- and 600 mg once-, 81–105 kg: 600 mg twice-, >105 kg 600 mg 
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once- and 800 mg once-daily). Treatment was started without a lead-in of pegIFN 
and RBV and continued for 12 weeks. HCV RNA was measured at week four and if 
positive every two weeks thereafter until undetectable. An undetectable HCV RNA 
was defined as HCV RNA <15 IU/mL (Roche) or <11 IU/ml (Abbott), with the PCR 
target not detected. For patients with HCV RNA still detectable at week 8, treatment 
could be prolonged to 24 weeks (response guided therapy). 
The primary endpoint of the study was sustained virological response at week 12 
after therapy (SVR12) within the patient group with an undetectable HCV RNA at 
week four (RVR4). 
Secondary endpoints were SVR12 in the whole intention to treat (ITT) population, 
SVR12 in patients that started therapy within 12 weeks after the presumed date of 
infection and RVR4 and SVR12 according to IL28 genotype. All patients were included 
in safety analysis of adverse events and quality of life was assessed by RAND-36 at 
baseline, week 4, 12 and 24. Utility score estimates were derived from the RAND-36 
using the ordinal health state evaluation model(140). A utility score of 1 is defined as 
the highest level of well-being and a score of 0 as death. 
To put the cure rate found in this study in perspective, historical controls were ret-
rospectively selected from the 10 study centers. Partly these controls were selected 
from the MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) 
cohort. The MOSAIC cohort is an open, on-going, prospective, observational cohort, 
initiated to study determinants and sequelae of acute HCV infection among HIV-
infected MSM. The MOSAIC is a collaboration between the Public Health Service of 
Amsterdam, five large HIV outpatient clinics in the Netherlands, which all also partici-
pated in the DAHHS, and the Stichting HIV Monitoring (SHM)(141). Study centers that 
did not participate in the MOSAIC cohort selected controls out of the Dutch ATHENA 
cohort, if available(142). Each center provided data of as much acute HCV genotype 1 
controls as possible. These controls had to have received at least one dose of pegIFN 
and RBV and started therapy between 2007 and 2013 at a time when the standard 
treatment duration was at least 24 weeks(136). ITT SVR12 data were obtained from 
these controls. Since it was not part of standard care to measure a HCV RNA at week 
12 after therapy, SVR12 in the historical controls was defined as the first HCV RNA 
measured from week 10 after therapy, but no later than week 48 after the end of 
therapy.
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statistical analysis
For the primary and secondary endpoints, a 2-sided confidence interval using the 
Wilson score method without continuity correction of the SVR12 was calculated. Due 
to the retrospective nature of the historical control group, no formal non-inferiority 
statistical comparison between the control group and the prospective ITT study 
population was planned. However, to compare SVR12 rates the chi- square test was 
used. The paired t-test was used for the comparison of utility scores between base-
line and treatment time points.
role of the funding source
MSD provided BOC as study drug and financially supported this investigator-initiated 
study. MSD had no role in the conduct and analysis of the data. 
results
From September 2013 until December 2014, 127 patients with a recent HCV infection 
were reported by 19 of the 27 existing HIV treatment centers across the Netherlands. 
Sixty-two patients were excluded because of genotype 4 (n=22), genotype 2 (n=1), 
infection > 6 months old (n=17), refused (n=13), spontaneous clearance without inclu-
sion (n=8), hepatitis B with cirrhosis (n=1)(figure 1). Sixty-five patients with an acute 
HCV genotype 1a/b infection were referred to or already in care in one of the 10 
study centers and were included. Eight patients did not initiate treatment because 
of spontaneous clearance (n=6), refusal after inclusion (n=1) and a serious adverse 
event before initiation of therapy (n=1). Finally, 57 patients initiated treatment and 
received at least one dose of pegIFN, RBV and BOC. In 48 of these 57 patients the di-
agnosis of acute HCV was based on a negative HCV RNA test result on stored plasma 
that was taken during the previous outpatient visit. To avoid drug-drug interactions 
with BOC, 26 patients switched from cART regimen before initiation of therapy. 
Nine patients switched to a rilpivirine and 17 to a raltegravir containing regimen. All 
patients remained HIV RNA undetectable after this cART switch. Except for a single 
patient who discontinued cART at his own initiative during HCV therapy.
Seventy-three historical controls from the same treatment centers, who initiated 
pegIFN and RBV based treatment during 2007-2013, were included. Baseline charac-
teristics are shown in table 1. 
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Assessed for eligibility 
(n=127)
Included (n=65)
Initiated treatment (n=57)
Excluded (n=62)
Genotype 4 (n=22)
Infection > 6 months old (n=17)
Refused (n=13)
Spontaneous clearance 
without inclusion (n=8)
Hep B with cirrosis (n=1)
Genotype 2 (n=1)
RVR4
(n=41)
Week 12 
EOT
 (n=40)
Week 24 
EOT
Completed (n=4)
Discontinued 
treatment 
(n=3)
n=40 n=4
Screeningsvisit only (n=8)
Non-RVR4
(n=16)
Discontinued 
treatment 
(n=1)
n=9
Week 12 
EOT 
 (n=9)
n=1 n=3
SVR12 analysis available
figure 1: Patient flow diagram. RVR4: rapid virological response at week 4, EOT: end of therapy
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Primary endpoint
All patients in the intervention group reached week 4 with 41/57(72%) achieving 
RVR4. All RVR4 patients had an undetectable viral load at end of therapy. One patient 
discontinued treatment at week 10 due to adverse events while subsequently achiev-
ing a SVR12. All 41 (100% with 95% confidence interval (CI), 91-100%) patients with 
a RVR4 achieved a SVR12 (figure 2).
table 1. Baseline characteristics 
Baseline characteristics DAHHS (n=57)
Retrospective cohort 
(n=73)
Sex, male 57 (100%) 73 (100%)
Age, years, median (IQR) 40 (34-47) 44 (39-49)
CD4 count, E9/L, median (IQR) 0·66 (0·45-0·79) 0·48 (0·40-0·68)
ALT, U/L, median (IQR) 160 (67-416) NA
Bilirubin. umol/L, median (IQR) 10 (6·5-13) NA
HCV genotype 1    
  subtype a 54 (95%) 61 (83·6%)
  subtype b 3 (5%) 8 (11%)
  unknown 0 4 (5·5%)
HCV RNA IU/mL, median (IQR) 222.000 (5615-1.235.000)
120.000 (2125-
1.215.000)
Treatment duration, weeks, median (IQR) 12 (12-12) 24 (23-26)
Interval infection-treatment, weeks, median 
(IQR) 22 (16·5-25) 23 (17-30)
Il28B genotype    
  RS 1297, CC 25 (42·5%)  NA
  RS 1297, non-CC 30 ( 57·5%)  NA
IQR: interquartile range, ALT: alanine-aminotransferase, NA: not available 
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figure2: Virological responses. (A) Virological response in RVR4 patients. (B) Virological response in ITT 
population. RVR4: rapid virological response at week 4, EOT: end of therapy, SVR12: sustained virological 
response at week 12
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secondary endpoints
SVR12 in ITT population
Next, we analyzed the ITT population, regardless of RVR4 result. A total of 49 patients 
were treated 12 weeks, four were treated 24 weeks and four patients discontinued 
therapy before week 12 (figure 1). Of the 16 patients without a RVR4, six had a de-
tectable but non-quantifiable HCV RNA load (<15 IU/l, target detectable) at week 4. 
Subsequently, nine of these 16 were undetectable at week 8 and continued therapy 
until week 12. Three discontinued before week 12. Out of the four patients that con-
tinued therapy until week 24, two had a detectable viral load at week 8 and were 
treated with pegIFN/RBV/BOC resulting in a SVR12. One patient had a detectable load 
at week 8 and was unsuccessfully treated with 12 weeks pegIFN/RBV/BOC followed 
by 11 weeks pegIFN/RBV. The last patient had an unknown load at week 8 and was 
treated successfully with 24 weeks pegIFN/RBV/BOC based on decision of the treat-
ing physician. 
The SVR12 rate in the ITT population was 49/57, 86% (95% CI, 75-93)(figure 2b). In 
total, 8 patients had a treatment failure of which 3 had a relapse, three discontinued 
therapy at a time that they still had a detectable viral load and two patients had a 
viral breakthrough. In all 3 patients with a relapse, phylogenetic analysis showed that 
the same strain was present at the time of failure, which excluded reinfection. An-
other patient with an RVR4 and HCV RNA negative 4 weeks after the end of therapy, 
had detectable HCV RNA 12 weeks after the end of therapy. Phylogenetic analysis 
showed that he was reinfected with a new HCV strain. 
SVR12 with treatment initiation within 12 weeks after infection
Another predefined secondary endpoint was the SVR12 rate in patients that started 
therapy within 12 weeks after the presumed date of infection. Five out of five pa-
tients (100%) treated within 12 weeks after infection had a SVR12 compared to 44/52 
(85%) after 12 weeks. Given the small number of patients in the former group, no 
conclusions can be drawn on this subgroup analysis. No correlation between the IL28 
genotype and SVR12 nor RVR4 rates was found (figure 3).
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SVR12 in historical controls
In the retrospective cohort, the ITT SVR12 result was 84% (95% CI, 73-90)(figure2b). 
Median treatment duration with pegIFN and RBV was 24 weeks (interquartile range 
(IQR) 23-26). As RVR4 testing was not part of the standard of care, results were only 
available in a minority of cases and therefore not shown. One patient was treated in 
the historical cohort for a previous acute HCV infection as well as in the prospective 
cohort.
The SVR12 rates in the prospective study population (86%) and the retrospective 
controls (84%) were not statistically significant (p=0.71).
Quality of life and safety
As expected, the quality of life decreased during therapy (-0.05 utility score, p<0.001) 
but was no longer different from baseline at the SVR12 time point (figure 4). 
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figure 3: Virological response according to IL 28B genotype. RVR4: rapid virological response at week 
4, SVR12; Sustained virological response at week 12, Il 28B genotype RS12979860 was available in 54 
patients.
U
til
ity
 s
co
re
figure 4: Change in utility score during treatment with peginterferon, ribavirin and boceprevir. EOT= End 
of Treatment, SVR12; time point of sustained virological response at week 12. For this analysis only avail-
able data of patients treated for 12 weeks were used. *** p<0.001
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During the study, four serious adverse events (grade 4) were documented. One 
myocardial infarction in a patient with a high-grade left anterior descending artery 
stenosis that was stented uneventfully (hemoglobin (Hb) 8.7 mmol/L at the time of 
the infarction). One suspected transient ischemic attack that resolved spontaneously 
and with normal MRI findings (Hb 6.6 mmol/L). One anemia (Hb 5.1 mmol/L) for which 
a transfusion was given and the RBV dose was decreased. All three patients contin-
ued their HCV therapy. The fourth SAE occurred in a patient that had not yet started 
HCV therapy (cerebral hemorrhage). Additionally, five grade 3 events were reported 
(depression, paradontitis, malaise, personality change, fatigue). At week 12, median 
decrease in Hb was 2.4 mmol/L (IQR 1.6-3.3). Grade 1 anemia was observed in 83%, 
grade 2 in 12% and 5% had no anemia at week 12. Dose reduction of RBV was done 
in six patients because of rapid Hb decline at week 4 or 8, but not because of grade 
3/4 anemia. Erythropoietin was not used in any of the patients. 
discussion
In this prospective multicenter study on the treatment of acute HCV in HIV positive 
patients, 12 weeks of BOC, pegIFN and RBV cured 100% of the patients that achieved 
a RVR4. Moreover, the ITT analysis showed a high SVR12 rate of 86%. This overall 86% 
cure rate was comparable to the 84% cure rate in patients treated with 24 weeks of 
pegIFN and RBV in the same study centers in the years preceding the prospective 
study. Hence, this study on the addition of BOC to pegIFN and RBV shows that treat-
ment duration can be halved in the majority of patients without loss of efficacy. 
Although less conclusive, the absence of a RVR4 was associated with a reduction 
in SVR12 from 100% to 50% (8/16). More specifically, the SVR12 rate of patients 
without RVR4 was 56% when treated 12 weeks and 75% when treated for 24 weeks. 
Therefore, although not formally tested in this study, treatment duration may have to 
be increased in patients without a RVR4. Also, the other way around, one may decide 
to discontinue treatment in patients without a RVR4 if side effects of treatment are 
problematic.
These data are in line with the results of a small single center pilot study by Fierer 
and colleagues, who reported a SVR12 rate of 84% in 19 patients treated with 12 
weeks of telaprevir, pegIFN and RBV(115). However, because of the small sample size 
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and the overrepresentation of patients with the favorable IL28B CC genotype, these 
data needed confirmation in a larger and more representative population. As such, 
our study is the largest study on the treatment of acute HCV with a DAA containing 
regimen ever performed. Also, the study population had a more representative IL28 
genotype distribution(63) (table 1). 
Because several antiretroviral drugs cannot be combined with BOC, 46% of the 
patients had to switch their cART to rilpivirine or raltegravir. In all these patients, who 
were treatment adherent, the HIV viral load remained undetectable throughout the 
study. Therefore, the need for a cART switch should not withhold patients or physi-
cians to start HCV therapy.
In the light of the rapid switch to more advanced DAAs in the treatment of chronic 
HCV in some resource rich countries, one may question whether there is any role for 
a treatment that consists of pegIFN, RBV and a DAA like boceprevir in the treatment of 
acute HCV. It could be advocated that nothing is lost when spontaneous clearance of 
HCV is awaited and HCV is treated with one of the many very effective interferon-free 
DAA combination therapies if after 12-18 months the infection has become chronic. 
However in most resource rich and almost all resource-limited countries, these ad-
vanced DAAs are not reimbursed for patients without substantial liver disease or not 
available at all. Given the fact that HCV can be considered a highly infectious disease 
in intravenous drug users as well as HIV positive MSM, untreated HCV patients will 
continue to transmit the virus and therefore continue to drive the HCV epidemic. 
So far, pegIFN based therapy will remain the only treatment available for acute HCV 
as long as interferon-free treatments are not registered for this indication. This is 
illustrated by the most recent EACS guideline, which still advices to treat AHCV with 
24 weeks pegIFN and RBV(96). Therefore, the 50% reduction in treatment duration 
with the addition of a first generation HCV protease inhibitor to pegIFN will make 
acute HCV therapy possible in more patients.
For countries in which DAAs are now available, this study clearly shows that also HIV 
positive patients with acute HCV can now benefit from a short treatment when a 
protease inhibitor is added to pegIFN and RBV. We think that second wave protease 
inhibitors like simeprevir or NS5 inhibitors, all better tolerated than BOC, are likely to 
lead to comparable results if combined with pegIFN and RBV. 
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In the end, it is plausible that we will be able to treat acute HCV without pegIFN or 
RBV. Although this is already advocated by the American Association for the Study 
of Liver Disease, this statement is without any supporting evidence. Acute HCV, with 
its extremely fluctuating HCV RNA plasma load, is a disease that immunologically 
and virologically differs from chronic HCV and the effects of pegIFN free regimens 
during acute HCV may therefore differ as well. This is illustrated by several abstracts 
of small pilot studies presented at the 2015 Liver Meeting. An ACTG study reported 
a SVR12 rate of 59% in patients treated with 12 weeks of sofosbuvir and RBV(143). 
Even lower SVR12 rates of 32% were seen in a study with 6 weeks of sofosbuvir and 
RBV(144). In contrast, when sofosbuvir was combined with ledipasvir for 4 weeks 
or with simeprevir for 8 weeks, the SVR12 rate was 100% (14/14 and 13/13 re-
spectively) (145). When confirmed in larger studies, this suggest high effectivity also 
during treatment of acute HCV when DAAs are combined. Future will tell if, for the 
treatment of acute HCV as well, the pegIFN era has come to an end.
Our study has some limitations. First, despite being able to reliably determine the 
date of HCV transmission by the use of stored plasma samples, which enabled us 
to treat patients in the early stage of disease, we cannot draw definite conclusions 
on the effect of a 12-week treatment for late acute/early chronic HCV stage (e.g. >6 
months but <12 months after infection). However, a recent study suggested that ini-
tiation of treatment with pegIFN and RBV could be delayed at least for some months 
without loss of efficacy(99). Furthermore in our study, patients started therapy at an 
estimated median of 22 weeks after infection. Therefore, it is likely that treatment 
of early chronic HCV (e.g. in the 6th or 7th month after infection) will not be much 
different. Second, our study design lacked a formal control group because a random-
ized study was considered unfeasible as in clinical practice new HCV infections are 
mostly diagnosed at the time they have become chronic. Also, we anticipated that 
the willingness to undergo a 24-week pegIFN based regimen was poor in the light of 
pending pegIFN-free regimens for chronic HCV. Therefore, we considered a large ran-
domized non-inferiority trial unachievable even with the multicenter study design in 
which an estimated 80% of the acute HCV infections diagnosed in HIV positive MSM 
in the Netherlands in 2014 were included. In our view, we created the most optimal 
comparator group, with genotype 1 infected patients that had been treated recently 
in the same study centers. Still, the comparator group may have been biased (e.g. by 
selecting the most motivated patients willing to undergo a 24-week pegIFN therapy). 
Additionally, the SVR12 rate of 84% in our control group was much higher than the 
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60% SVR12 published in a review by Rockstroh and colleagues(95). However, the 
data of our control group are in line with Dutch data published in 2011 and recent 
data from the Swiss cohort(123, 141).
In conclusion, 12 weeks of triple therapy consisting of pegIFN, RBV and BOC results 
in very high cure rates in those patients achieving a RVR4 with acceptable toxicity 
and therefore is a good treatment option in HIV-infected patients with an acute HCV 
infection.
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abstr act
Treatment of hepatitis C virus infections (HCV) in HIV co-infected patients improved 
substantially when HCV protease inhibitors became available. CYP3A4 inhibition by 
boceprevir may influence the metabolism of the certain antiretroviral drugs like ril-
pivirine. In this study 12 HIV positive patients treated with rilpivirine and boceprevir 
had blood samples taken together with an ECG measurement before and during acute 
HCV treatment. Treatment with boceprevir resulted in increased rilpivirine AUC0-24h 
from 3.8 mg∙h/L to 6.5 mg∙h/L, but did not result in increased QTc-intervals. 
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introduction
In 2012, hepatitis C virus (HCV) protease inhibitors were the first direct-acting 
antivirals (DAAs) that led to an improved treatment response when combined with 
peginterferon-alfa and ribavirin for the treatment of HCV infections. However, when 
used in HIV-positive patients, treatment with DAAs is more complicated regarding 
possible drug-drug interactions (DDI) with combination antiretroviral therapy. The 
nonnucleoside reverse transcriptase inhibitor rilpivirine is a CYP3A4 substrate 
and therefore potentially interacts with boceprevir, a CYP3A4 inhibitor. Based on a 
healthy volunteer DDI study, exposure to rilpivirine increased with 39% when given 
together with boceprevir (146). This increased exposure did not lead to clinically 
significant corrected QT (QTc) prolongation during short-term administration in the 
healthy volunteers. Therefore the product label of boceprevir states that the drug can 
be coadministered with rilpivirine; this also holds for other HCV protease inhibitors 
and CYP3A4 inhibitors, such as telaprevir and simeprevir(146-148). 
We performed a subanalysis within the Dutch Acute HCV in HIV Study (DAHHS) to 
describe the pharmacokinetic interaction between boceprevir and rilpivirine in HIV/
HCV-positive patients and the possible effects on QTc-interval prolongation(149).
methods
In the DAHHS, 57 HIV-positive patients were treated for an acute HCV infection with 
12 weeks of weight-based pegylated interferon-alfa (pegIFN), ribavirin and boceprevir 
800 mg thrice daily(150). In this substudy patients treated with rilpivirine 25 mg daily 
combined with two nucleos(t)ide reverse transcriptase inhibitors were included. Pa-
tients were instructed to take rilpivirine together with at least a 500 Kcal meal. Blood 
samples were taken before the start of HCV therapy (T0) and at week 4 of therapy (T4) 
during the elimination phase of the drug (t=4-24h after administration). Concurrently, 
with the blood draw, a single 12-lead ECG was recorded in all participants at T0 and 
T4. Heart rate corrected QT was calculated using Bazett’s formula. Rilpivirine plasma 
concentrations were analyzed by a validated reversed-phase ultra-performance 
liquid chromatographic method with ultraviolet detection (linear calibration range 
(0.0063-3.75 mg/L). Concentration-time data were analyzed using nonlinear mixed-
effect modeling (NONMEM version 7.2; ICON, Dublin, Ireland). The effect of boceprevir 
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and alanine-aminotransferase (ALT) on rilpivirine apparent clearance (CL/F) was 
evaluated. Area under curve (AUC)0-24h was calculated using individual estimations 
for CL/F and dose. The correlation between AUC0-24h and QTc time was analyzed using 
linear regression.  
results
Twelve male patients (11/12 white people) were included. Median age was 38 years 
(interquartile range (IQR) 33-43). Patients had a median ALT of 126 U/l (IQR 29-198) 
with no signs of liver failure at T0 and their median ALT at T4 was 36 U/l (IQR 28-39). In 
all patients the HIV viral load was fully suppressed at both time points. One out of 12 
patients had concomitant medication potentially influencing the rilpivirine metabo-
lism or QTc time (acetylsalicylic acid 80mg daily, prasugrel 10 mg daily, pravastatin 
40 mg daily, perindopril 2mg daily)
Median rilpivirine concentration at T0 was 0.16 mg/L and at T4 0.26 mg/L. In the indi-
vidual patients, the absolute rilpivirine concentration increased at T4 from +0.01mg/L 
(8%) to +0.10mg/L (63%), when measured at the same time point after intake. 
Pharmacokinetics of rilpivirine were described using a one-compartment model with 
fixed values for the absorption rate (ka=0.7 h-1) and volume of distribution (Vd=152L) 
based on literature. CL/F decreased from 7.2 to 3.8 L/h when patients were treated 
with boceprevir (relative SE 14%, p<0.005). In the simulated pharmacokinetic profile, 
a clear decrease in CL/F and AUC0-24h is seen (figure 1). This DDI explained 34% of the 
variability in CL/F. The remaining variability of CL/F was 44% (relative SE 13%). No 
significant correlation between ALT and CL/F was seen. Measured QTc-intervals were 
not correlated to the calculated rilpivirine AUC0-24h. Patients without boceprevir had 
a median rilpivirine AUC0-24h of 3.8 mg/L/h with corresponding QTc interval of 382 
ms (range 355-425 ms) and patients treated with boceprevir had a median rilpivirine 
AUC0-24h of 6.5 mg/L/h and a corresponding QTc interval of 384 ms (range 349-425 ms).
discussion
This study showed that the concomitant use of boceprevir in HIV-positive patients 
treated with rilpivirine decreased the rilpivirine CL/F, resulting in increased rilpiv-
Safety of rilpivirine and boceprevir co-administration in HIV-infected patients treated for acute HCV 61
5
irine AUC0-24h from median 3.8 mg/L/h to 6.5 mg/L/h. This DDI could explain 34% 
of the variability in CL/F seen in these patients, but did not result in increased QTc-
intervals. The AUC0-24h values seen in the patients without boceprevir treatment were 
comparable to values described previously(151). 
The increase in rilpivirine AUC0-24h (71%) we found in this study is higher than pre-
viously described in healthy volunteers (39%)(146). This suggests that data from 
healthy volunteers cannot be translated one on one to HIV-infected patients.
The main limitation of the study was the limited number of samples per patient that 
were obtained, one before and one during treatment with boceprevir. As a conse-
quence, only CL/F and its variability could be estimated. These values changed after 
adding the effect of boceprevir treatment, resulting in a significant improvement of 
the model (p<0.005). In literature, the influence of race, gender and food on rilpiv-
irine CL/F is described. Unfortunately, this is not evaluated in this study as gender 
and race were male and predominantly Caucasian(151-153). 
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figure 1: Rilpvirine concentrations with and without boceprevir. Median pharmacokinetic profile and 
range of rilpivirine in patients treated with (black) and without (grey) boceprevir.
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This is the first analysis of rilpivirine DDI interactions with boceprevir in HIV-infected 
patients. More effective interferon-free treatment options have recently become 
available for the treatment of chronic HCV. However, they are not approved for acute 
HCV and given the high costs, their availability is currently limited to a very small 
number of patients. Therefore, and given the results of the DAHHS in which 86% of 
the patients could be cured of their acute HCV with a 12-week treatment, it is likely 
that boceprevir will continue to be used for some time. We show that it can be safely 
combined with rilpivirine. 
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abstr act
Introduction
Within HIV positive men having sex with men the epidemic of hepatitis C (HCV) is 
ongoing. Transmission of resistant variants of HCV after failure of treatment with di-
rectly acting antivirals (DAA) could be a major threat to the effectivity of therapy. We 
determined whether HCV resistant variants to DAAs were prevalent amongst patients 
with an acute HCV infection diagnosed in 2013 and 2014 in the Netherlands.
Methods
Target enrichment for viral nucleic acid separation and deep sequencing were used 
to recover whole HCV genomes of 55 patients with an acute HCV infection. The ge-
nomes were assembled by de novo assembly and analysed for known DAA resistance 
mutations, phylogeny and mixed infections before and during acute HCV therapy.
Results
In acute HCV infected treatment-naïve patients the relevant resistance associated 
substitutions were in the Q80K (40%) in NS3/4a, the M28V (22%) and Q30H with 
Y93H (2%) in the NS5A and the M414T (2%) or S556G (2%) the NS5b gene. Patients 
who failed on boceprevir, peginterferon and ribavirin therapy developed mutations 
in the NS3 gene at position T54A and R155K.
Conclusion 
The presence of resistant variants implies that the combination of DAAs should be 
carefully selected when these patients are treated with interferon-free DAA.
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introduction
Since very effective and well-tolerated direct-acting antivirals (DAAs) have become 
available, hepatitis C (HCV) has progressed from a difficult to treat to an almost 
universally curable infection. These new DAAs target specific regions in the HCV 
genome, resulting in very high cure rates when given in combination. Although, the 
first generation DAAs have increased the cure rates of genotype 1 infection, some 
continue to fail treatment potentially due to acquired resistance against the DAA 
and/or transmission of already resistant clades. Recently, HCV became endemic as 
a sexually transmitted infection amongst HIV positive men who have sex with men 
(MSM)(119). In this specific patient population, the risk of transmitted DAA drug resis-
tance is clearly present as ongoing sexual transmission of HCV occurs. 
Active surveillance of liver enzymes during antiretroviral therapy facilitates the 
early identification of HCV infections. In 2014, 99 HIV positive patients with a newly 
acquired HCV infection were identified through active surveillance in a multicenter 
study in the Netherlands(125). As part of the Dutch Acute HCV in HIV Study (DAHHS), 
most of these newly identified HCV positive patients were treated with peginterferon 
(pegIFN), ribavirin (RBV) and boceprevir (BOC)(130). At the same time they consented 
to donate blood for further analysis and this in turn allowed us to investigate the 
prevalence of DAA resistance amongst acutely HCV infected patients in an era when 
the first generation HCV protease inhibitors boceprevir and telaprevir had been in 
use for 2 years in the Netherlands.
Current methods for phylogenetic and antiviral drug resistance genotyping include 
RT-PCR based enrichment techniques of small regions of the genome with subse-
quent Sanger population sequencing or non-enriched direct next generation se-
quencing (186, 187). Due to the highly variable genome of HCV, especially between 
genotypes the design of RT-PCR primers that cover the whole genome of all geno-
types has been proven to be virtually impossible. Whole genome sequencing (WGS) 
directly from clinical samples can contribute significantly to the understanding of 
clinical population structures, including minority populations, mixed infections and 
resistance mutations. However, with the current methodologies, non-enriched direct 
next generation sequencing, very high viral loads (> one million international units) 
are required for full genome deep sequencing analysis. We have previously shown 
that target enrichment, which uses custom designed 120-mer RNA nucleotides that 
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span the entire target genome, can recover (by hybridization) low copy numbers of 
viruses from clinical samples with sufficiently high sensitivity and specificity to en-
able ultra-deep whole genome sequencing(188, 189). In this study, we apply the 
target enrichment approach directly to clinical HCV positive specimens. The goals 
of this study were 2-fold. First we wanted to demonstrate the effectiveness of this 
sequencing method by deep sequencing 55 HCV genomes and generating close to 
complete genomes with high read depth. Secondly, using this method we want to 
examine the prevalence of transmitted DAA resistance among a relatively large group 
of patients that became HCV infected in the DAA era. 
methods
Within the DAHHS, 65 patients with an acute HCV genotype 1 were included of which 
57 were treated with 12 weeks of pegIFN, RBV and BOC. Patients initiated treatment 
within 26 weeks after their HCV transmission. At baseline, week 4 during treatment 
and 12 weeks after treatment, blood was drawn for additional analysis. All patients 
that initiated treatment with a viral load above 1000 IU/ml (CAP/CTM, V2, Roche 
diagnostics or Abbott Realtime M2000) were selected for WGS. Patients with a poor 
response to therapy at week 4 (above 1000 IU/ml) and patients who relapsed after 
treatment were analyzed for acquired resistance. All patients signed a written in-
formed consent. This study was registered under NCT01912495.
double stranded cdna synthesis
Nucleic acid was extracted from EDTA plasma using the DSP Virus/Pathogen kit on 
the QiaSymphony with the complex200 protocol and nucleic acid was eluted in 60ul. 
Approximately 55 μl of the RNA extractions were concentrated down to ~11 μl and 
the complete 11 μl were used for first strand cDNA synthesis using the Superscript III 
Reverse Transcriptase kit (Life Technologies, 18080093) following the manufacturer’s 
instructions, which required Random Primers (Life Technologies, 48190011), 10 mM 
dNTP Mix (Life Technologies, 18427013) and RNaseOUT (Life Technologies, 10777019). 
For second strand cDNA synthesis 20 μl from the first stand synthesis were processed 
with the Second Strand cDNA synthesis kit (NEB, E6111) following the manufacturer’s 
instructions. All of the ds cDNA was purified using the Genomic DNA clean and con-
centrator TM  -10 kit (Zymo Research, D4011) following the manufacturer’s instruc-
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tions and using 5x binding buffer and eluting in 30 μl of ultrapure nuclease free H2O 
(Life Technologies, 4387936). 
sureselectXt target enrichment: rna baits design 
The 120-mer RNA baits spanning the length of 953 GenBank HCV partial and complete 
reference genomes were designed using an in-house PERL script developed by the 
PATHSEEK consortium. The specificity of the baits was verified by BLASTn searches 
against the Human Genomic plus the Transcript database. The custom designed HCV 
bait library was uploaded to SureDesign and synthesised by Agilent Technologies. 
sureselectXt target enrichment: library preparation, hybridisation and 
enrichment 
The purified ds cDNA were quantified using the Qubit dsDNA HS assay kit (Life 
Technologies, Q32854) and between 200-500 ng of ds cDNA was sheared for 150 
seconds, using a Covaris E220 focused ultra-sonication system (PIP 175, Duty factor 
5, Cycles per Burst 200). End-repair, non-templated addition of 3’ poly A, adapter 
ligation, hybridisation, PCR (12 cycles pre-capture and 18 or 22 cycles post capture) 
and all post- reaction clean-up steps were performed according to the SureSelectXT 
Automated Target Enrichment for Illumina Paired-End Multiplexed Sequencing 200 
ng protocol (version F.2) on the Bravo platform WorkStation B from Agilent Technolo-
gies. All recommended quality control steps were performed on the 2200 TapeStation 
from Agilent Technologies.
illumina sequencing
The samples were sequenced in multiple runs on an Illumina MiSeq sequencing 
platform with 500  bp v2 reagent sets. Base calling, adapter trimming and sample 
de-multiplexing were generated as standard producing paired FASTQ files for each 
sample. 
sequence data analysis
Trimming and quality control
Genome mapping, assembly and finishing was performed using CLC Genomics 
Workbench (version 7.5/7.5.1) including the CLC Microbial Genome Finishing Module 
(version 1.4) from Qiagen. For each data set, all read-pairs were subject to quality 
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control and reads were quality trimmed based on a cut-off of an average Phred score 
of 30 and the presence of ambiguous nucleotides. 
Whole genome consensus sequencing
First an unbiased sequencing approach was taken using de novo assembly. For de 
novo assembly all trimmed reads from each sample were pre-filtered against a 
GenBank reference list containing 953 partial and complete HCV genomes. From the 
trimmed, paired HCV reads a subset of 50,000-100,000 reads were subsampled and 
used for de novo assembly. The contig(s) generated from each sample were aligned 
against 19 HCV reference genomes including different HCV genotypes (1a-6k) and if 
required, contig(s) were manually assembled and reversed complemented based on 
the best matching reference. All trimmed reads were mapped back to the generated 
contig(s) and duplicated mapped reads were removed. This was followed by local 
realignment, indels and structural variants were identified based on unaligned ends 
and locally realigned a second time. De novo consensus sequences were extracted 
using a threshold of 6x coverage and insertion of ‘N’ ambiguity symbols where cover-
age was low. 
Some samples failed to generate contig(s) using de novo assembly due to a low 
number of HCV sequence reads (samples with low viral loads). For samples with a 
high number of HCV reads which did not generate contigs using de novo assembly, 
reference based mapping was performed. All trimmed reads were mapped against a 
GenBank reference list containing 953 HCV genomes to identify the best matching 
HCV reference. The best matching reference was identified by choosing the reference 
sequence with highest percentage of total sequence coverage (>30% as minimum) 
together with highest number of mapped reads. Each sample was mapped to the 
best matching reference using high stringency affinity gap cost parameters (mis-
match cost 5, insertion cost 3, deletion cost 3, insertion open cost 6, deletion open 
cost 6, deletion extend cost 1, length fraction 0.8 and similarity fraction 0.9). The 
trimmed mapped reads were locally realigned, indels and structural variants were 
identified based on unaligned ends and locally realigned a second time. Consensus 
sequences were extracted using a threshold of 6x coverage and insertions of ‘N’ 
ambiguity symbols where coverage was low. To investigate whether dual infection 
was the reason for de novo assembly failure, unmapped reads were used to find the 
second best matching reference out of the 953 HCV genomes. Minimal requirements 
for reference coverage were set at >30% of reference coverage and number of reads 
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mapping to the second best matching reference needed to be more than 5% of the 
number of reads mapping to the best matching reference. Using the second best 
matching reference a consensus sequence was generated using the same parameters 
as described above.
Phylogenetic analysis
Consensus sequences from the samples were aligned to full genome consensus 
genotype references obtained from the Los Alamos HCV sequence database (2014 
reference set) using Bioedit version 7.2.5(190). Sequences were cut to the same 
length which resulted in a 7632 nucleotide length alignment. Best fitting evolutionary 
substitution model was determined using BIC model testing in the CLC workbench 
version 8.0. Phylogenetic trees were made using Mega version 6 using the best fit-
ting model (General Time Reversible with invariant sites and a gamma distribution 
of among site rate heterogeneity (GTR+I+G) with bootstrap value determined by 100 
bootstrap resampling of the data(191). In addition pairwise distances were calculated 
using the Maximum Composite Likelihood model with a 100 bootstrap resampling 
of the data. The rate variation among sites was modelled with a gamma distribution 
(shape parameter = 5).
Directly Acting Antivirals (DAAs) resistance analysis
Positions of interest for DAA resistance (see tables S1-S3 in supplementary material) 
were identified in the GenBank reference HCV strain H77 polyprotein gene, complete 
codon (accession no. AF011751). All trimmed reads from each sample were mapped 
against the genes of interest (NS3/NS4a, NS5a and NS5b) using the default affine gap 
cost parameters described above followed by removal of duplicated mapped reads. 
The trimmed mapped reads were locally realigned, indels and structural variants 
were identified based on unaligned ends and locally realignment was performed a 
second time using the identified indels and structural variants as guidance track. 
Low frequency variant detection was called with a min. coverage filter of 20x and a 
min. count of 5 independent reads. Variant frequencies were called down to 1% if 
the coverage allowed for it (see table S4 in supplementary material). A relative read 
direction filter was used and variants with a read direction distribution significantly 
different from the expected were removed. 
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results
sample selection
DAHHS baseline samples were available from 50 of the 65 patients (table 1). Fifteen 
patients were excluded because of samples being not available (n=12), viral load 
<1000 IU/ml (n=3). Two patients with a poor response to therapy at week 4 (above 
1000 IU/ml) and three patients who relapsed after treatment were analyzed for 
acquired resistance. The total number of samples analyzed was 55.
result of whole genome sequencing
In this study we performed WGS directly on clinical specimens from 55 HCV posi-
tive samples. Using de novo assembly, we generated complete genomes (>90-100% 
recovery of the HCV genome) from 51 samples, partial genomes (>80-90% recovery 
of the HCV genome) from 3 samples and 1 low titre sample (3070 IU/ml) failed to 
generate a HCV genome (<50% recovery of the HCV genome) (table S5 in supple-
mentary material). Overall the sequence data showed a strong correlation between 
the number of HCV copies in the diagnostic sample and the mean read depth across 
the genome (figure 1). From this data-set the lower limit of detection for WGS of HCV 
directly from clinical samples was estimated to a diagnostic value of ~3500 IU/ml.
table 1. Baseline characteristics
n=50  IQR  
male   100%  
age years 40 (33-47)
genotype 1 a 98%
b 2%
HCV viral load IU/ml 439.500 (40.450-2.362.500)
Cd4 E6/mL 650 (450-833)
Il 28B genotype
CC 38%
non-CC 54%
unknown   8%    
Characteristics of patients analysed at initiation of treatment. All results are presented as median with 
interquartile range (IQR) or as percentage.
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Four samples (Na01, Ad04, Ef06, Ol12) failed de novo assembly despite having >90% 
on-target reads (reads mapping to HCV). Reference based mapping showed, from 
the highly variable region of the HCV E2 gene (H77 numbering 872-1968), an inter-
subtype (GT1A plus GT1A) dual infection in patient Ol12 (supplemental figure 1). For 
the samples from patient Na01 and Ad04, the second best mapping reference did not 
generate sufficient reference coverage i.e. to generate a second consensus sequence 
indicating that these patients did not have a dual infection. The first and second best 
reference mapping consensus sequence from patients Ef06 rooted very close to each 
other in the phylogenetic tree, suggesting strain variation rather than dual infection 
within the patient. Samples from patients Oc03 and Ob02 were used as controls and 
the reference based mapping approach, using the best and second best matching 
reference, generated two identical consensus sequences from each patient, both of 
which were identical to the de novo generated sequences (data not shown).
Phylogenetic analysis
Using the consensus sequences obtained by de novo assembly and the four best 
sequences obtained by reference based mapping a phylogenetic tree was generated. 
Consensus reference sequences from the Los Alamos 2014 HCV full genome refer-
ence set were added (figure 2). The figure shows several clusters suggesting various 
networks in which sexual transmission of HCV occurred.
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figure 1: Figure 1 shows the relationship between the HCV copy number identified in the diagnostic 
sample (IU/ml x 2.7 = copies/ml) and the mean read depth obtained across the whole HCV genome. 
98 Chapter 7
91 
 
 Ec03 Baseline 
 Ep16 
 Af06 
 Ob02
 Na01 
 En14 
 Of06
 Uc03
 Eo15 
 Ua01
 Ek11
 Mf06
 Me05 
 Ed04 
 Ref.CON 1a 
 Ei09
 Ra01
 Sd04 
 Aa01
 Ot20
 Eb01 
 Mc03
 Es19
 Os19
 Oe05 baseline
 Oe05 week 24
 Ea01
 Eg07 
 ma01 
 Eh08 
 Od04 
 Ec03 week 24
 Em13
 Ol12
 On14 baseline 
 On14 week 4 
 Ub02
 Ee05
 Sc03 
 Oa01
 Ag07
 Oc03
 Ac03 
 Ef06 
 Ab02
 Ae05
 Og07
 Eq17
 Ref.CON 1c
 Ref.CON 1b
 Md04 baseline
 Md04 week 24
 Ref.CON 4a 
 Ad04 GT4 
 Ref.CON 6a 
 Ref.CON 3a
 Ref.CON 5a 
 Ref.CON 2a 
 Ref.CON 2b100
100
100
100
100
100
100
100
100
100
98
100 
100
100 
100
100
100
95
100
100 
100
95
100
100
100
100
100
95
100
100
100
100
100
100 
100
100
96
0.01
Figure 2. Maximum likelihood phylogenetic tree of full length HCV sequences 
figure 2. Maximum Likelihood tree based on the General Time Reversible model. The percentage of trees 
in which the associated taxa clustered together is shown next to the branches. A discrete Gamma dis-
tribution was used to model evolutionary rate differences among sites (5 categories (+G, parameter = 
0.8480)). The rate variation model allowed for some sites to be evolutionarily invariable ([+I], 0.0000% 
sites). There were a total of 7632 positions in the final dataset.  All samples are baseline samples, except 
for samples with ‘week 24’ or ‘week 4’added. These samples are taken at week 4 during or 12 weeks after 
the end of a 12-week treatment with boceprevir, peginterferon and ribavirin.
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Variant detection
After exclusion of dual infection, four samples showed high variation between the 
viral quasispecies: two at baseline (Ef06, Na01) and a baseline together with week 
4 (Ad04). Low frequency variant detection showed a high number of heterozygous 
single nucleotide variant (SNV) sites throughout the genome in patient Ef06 and 
Na01 compared to a homogenous sample from patient Oe03 (supplementary mate-
rial Figure S2a-c). The variant data indicated an approximate 50:50% mix in patient 
Ef06 and a 40:60% mix in patient Na01. Low frequency variant detection was per-
formed on the two samples from patient Ad04 and all shared heterogeneous biallelic 
SNV sites were identified to assess the ratio of the variants. The variant data from 
this patient indicated an approximate 50:50% mix of the two genotype 4 variants at 
baseline and after four weeks of treatment the ratio changed to approximate 10:90% 
mix (figure 3). 
Directly Acting Antivirals (DAAs) resistance analysis
Detailed information on the target genes NS3/4a, NS5a and NS5b was extracted from 
the WGS data and mutations known to be associated with DAA resistance could be 
excluded or were identified in all baseline samples down to a 1% variant frequency 
level. In the acute HCV cohort DAA Resistant associated substitutions (RASs) were 
identified in 31 of 50 baseline samples. In 18 of the samples no RASs were identified 
and in one sample coverage was too low for accurate resistance analysis. In 38.7% 
(12/31) of the samples a single DAA RASs was identified and in 61.3% (19/31) mul-
tiple RASs were detected. The most prominent RAS in NS3 was Q80K in 40% of the 
samples. In the NS5a genes both M28V (22%) as well as H58P (26%) were found as 
90 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 1000 2000 3000 4000 5000 6000 7000 8000 9000
SN
V 
fre
qu
en
cy
 (%
)
HCV genome (nucleotides)
Shared heterozygous biallelic SNV sites
Ad04 baseline
Ad04 week 4
figure 3: Figure 3 illustrates the shared heterozygous biallelic single nucleotides variant sites in patient 
Ad04 at baseline (dark grey) and after week 4 of treatment (light grey). The horizontal axis shows the 
HCV genome in nucleotides and the vertical axis shows the biallelic variant frequencies in percentage.
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figure 4: Figure 4 illustrates the known DAA resistance associated substitutions identified at baseline 
(n=50) in the acute HCV cohort. The vertical axis shows the proportion of patients (in percentage) in 
which the different mutations were identified. a) Known DAA resistance associated mutations in NS3/
NS4a, b) Known DAA resistance associated mutations in NS5a and c) Known DAA resistance associated 
mutations in NS5b. Dark gray: variant frequency >50%, light gray: variant frequency <50%.
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dominant substitutions with in 8 of 49 being combined. The A421V (18%) and I585V 
(12%) were seen as most occurring RASs in the NS5b gene (Figures 4 a/b/c). Remark-
ably, in patient Me05, an uncommon combination of Q30H and Y93H occurring at 
high frequency (both 99%) in NS5a was seen. This combination is associated with 
93.136 fold resistance in EC50 against daclatasvir (192).
Development of RASs during therapy
Insufficient response at week 4 of therapy
Patient Ad04 was diagnosed with genotype 1a and had a baseline HCV viral load 
of 16.9x106 IU/ml. At week 4 the patient presented with a viral load of 23.1x106 IU/
ml and reported that he had discontinued therapy one week before. BOC resistance 
associated mutations were not identified in patient Ad04 at the two sampling points 
(Supplementary table 6). Surprisingly, based on the sequence results this patient 
turned out to have a genotype 4 infection at both time points instead of the geno-
type 1.
Patient On14 was diagnosed with genotype 1a with a baseline viral load of 16.4x106 
IU/ml. At week four of treatment he had a viral load of 5790 IU/ml and reported 
to be treatment adherent. No baseline DAA RASs were detected, but after four 
weeks of therapy 2 BOC associated mutations (T54A and R155K) were identified 
(Supplementary table 6) at 53.3% and 14% variant frequencies, that result in a 10-
fold decrease in BOC susceptibility (Tong et al, Biochemistry).
Relapse 12 weeks after treatment
Patient Ec03 was treated for 12 weeks and had an undetectable HCV RNA at week 
4, but became detectable at week 12 after treatment. The baseline and week 12, 
post-treatment samples showed two different HCV genotype 1a strains (figure 2, 
Ec03 Baseline and Ec03 week 24). Second best reference approach showed that the 
genotype present at failure was not detected at baseline (data not shown). Therefore, 
WGS proved that this patient did not have a relapse but a reinfection.
Patient Md04 (genotype 1b) and Oe05 (genotype 1a) were successfully treated for 12 
weeks. Both had a detectable viral load at week 4 of treatment but became negative 
at week 8. Both patients became detectable at week 12 after therapy and strains 
in both cases were identical to the baseline strains. At the time of relapse, patient 
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Oe05 showed a R155K dominant (92%) mutation, which is associated with major 
BOC resistance. In contrast, Md04 had no known acquired BOC mutations at relapse 
(supplementary figure S3a/b).
discussion
We have previously shown that targeted-enrichment is a useful approach to recover 
complete viral or bacterial genomes directly from clinical specimens without any 
prior amplification or in vitro culture (188, 189, 193, 194). Here we use this novel 
methodology to recover complete HCV genomes directly from clinical HCV positive 
plasma samples. The combination of whole-genome enrichment and deep sequenc-
ing allowed us to recover close to complete genomes for 98% of the samples, to 
perform a comprehensive DAA resistance and phylogenetic analysis and to assess 
the population structure in four samples with high variant numbers. 
In this study, we hypothesized that patients with an acute HCV infection in 2013 or 
2014 could theoretically have been infected with a resistant variant. Because failure 
to the first generation protease inhibitors was common, treatment experienced vire-
mic patients could have transmitted their acquired resistant variant to their sexual 
partners. It is reassuring that the presence of typical boceprevir or telaprevir RASs in 
these treatment-naïve patients was limited and potentially observed in only three 
cases (6%). This involved the V36M substitution, which is associated with low level 
resistance (7 fold change in EC50) and V55I which is also associated with low level 
resistance (1.4 fold increase in EC50) (195, 196). However, these substitutions can 
occur also as natural variants so transmission from DAA failing patients cannot be 
proven (197).
As soon as the first HIV drugs became available, transmission of drug resistant HIV 
was observed among MSM (198, 199). This has led to the recommendation to test for 
transmitted drug resistance before the start of antiviral therapy in international HIV 
treatment guidelines. Recently, the first case of transmitted HCV DAA resistance was 
described by Franco and colleagues(181). As far as we know, this study is the largest 
of its kind that used whole genome deep-sequencing to look at the prevalence of 
transmitted DAA resistance in patients that became HCV infected in the DAA era.
Use of whole genome sequencing in the Dutch Acute HCV in HIV study 103
7
Additionally, we observed a 40% prevalence of the Q80K substitution in the NS3/4a 
region. This substitution is found almost exclusively in genotype 1a(180). Our findings 
correlate with proportions found in AHCV cohorts in Germany (56%) but is higher 
than was seen in England (16%)(200, 201). However, in a recent Australian study, 
only 4% of the acutely infected patients had a Q80K substitution(202). The Q80K 
substitution results in a median 11-fold increase in the EC50 of simeprevir (IQR 7.4-13) 
against HCV genotype 1a. This has been associated with increased treatment failure 
with simeprevir, pegIFN and RBV and therefore resistance testing is advised(203, 
204). In contrast, recent studies have shown that there is no impact on the overall 
response when simeprevir is given for 12 weeks in combination with sofosbuvir for 
chronic HCV (205, 206). However, when acute infections are treated with very short 
regimens (i.e. 8 week a simeprevir/sofosbuvir) and other negative predictors like high 
baseline viral loads are present, the Q80K substitution could have an impact on the 
sustained viral response rate(145).
At the time the patients in the current study became HCV infected, NS5a or NS5b 
inhibitors were not yet in clinical use. Therefore, the RASs that we detected in NS5a 
and NS5b were not selected by drug exposure but occurred as natural variants. The 
NS5a M28V substitution was found in 22% of the patients. This substitution could 
influence the effectivity of ombitasvir and elbasvir modestly(180). The reduced 
treatment success that was observed in patients with a M28V substitution that were 
treated with grazoprevir and elbasvir resulted in the first drug label that recommends 
resistance testing for treatment naïve genotype 1a patients(207). In a single other pa-
tient, the combination of the Q30H and Y93H substitutions in NS5a was documented, 
which results in high level resistance to NS5a inhibitors(180). Within the NS5b gene 
we found the clinical relevant M414T (2%) and the S556G (2%) substitutions. These 
substitutions can occur as a naturally occurring polymorphism but are also associ-
ated with virological failure in response to dasabuvir(180, 208). 
Currently, there is ongoing debate as to whether resistance testing in treatment naïve 
patients is indicated. The presence of well-defined clusters of HCV transmission to-
gether with ongoing sexual transmission and the presence of a highly resistant HCV 
strain in one of our patients, clearly shows the potential of the transmission of a NS5a 
resistant virus. If patient Me05, with the Q30H and Y93H substitutions in NS5a, had 
been founder of a cluster (figure 2), this could have resulted in loss of susceptibility 
to all NS5a inhibitors in the entire cluster. With a median of 10 sexual partners per 
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6 months found in a recent study, this resistant variant could rapidly spread among 
MSM(209). Therefore, in particular if unexplained treatment failure is observed, base-
line resistance testing may be indicated and certainly if treatment failure would be 
observed in >1 patient from a potential transmission cluster.
In conclusion, this study showed that a WGS technique that used target enrichment 
can be successfully applied to patients with an acute HCV. It was able to detect mixed 
infections and resistance associated mutations that were present at baseline as well 
as at the time of treatment failure. Fortunately, at the moment no convincing evi-
dence of transmitted drug resistance was found. However, the presence of naturally 
occurring resistant variants could result in low treatment response rates when certain 
regimens are used.
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Supplementary figure  1: Maximum likelihood phylogenetic tree of full length HCV sequences with incor-
poration of 4 samples analyzed with reference based mapping
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table s1. Mutations known to be associated with resistance in NS3/NS4a
Amino acid 
position (per 
gene)
Sensitive aa Amino acid 
in ref. H77 1a  
AF011751
3-letter code in 
H77
Resistant amino acid
36 V V Val M/L
41 Q Q Gln R/N/L/K/H
43 F F Phe V/S/L/I
54 T T Thr S/A
55 V V Val I/A
56 Y Y Tyr H
80 Q Q Gln R/N/L/K/H
95 T T Thr S
109 R R Arg K
122 S S Ser S/R/N/G/A
132 I I Ile V
155 R R Arg W/T/S/Q/M/K/G
156 A A Ala V/T/S/N/G/F
168 D D Asp Y/N/I/H/G/E/A
170 V I Ile A
Table S1 lists the known direct acting antiviral resistance associated mutations in NS3/NS4a which was 
assessed in this study.
table s2. Mutations known to be associated with resistance inNS5a
Amino acid position 
(per gene)
Sensitive aa Amino acid in ref. 
H77 1a  AF011751
3-letter code in H77 Resistant amino 
acid
28 M/L M Met V/T
30 R/Q Q Gln E/H/Q/R
31 L L Leu F/M/V
37 V V Val M
58 H H His P
93 Y Y Tyr C/H/N
Table S2 lists the known direct acting antiviral resistance associated mutations in NS5a which was 
assessed in this study.
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table s3. Mutations known to be associated with resistance in NS5b
Amino acid position 
(per gene)
Sensitive aa Amino acid in ref. 
H77 1a  AF011751
3-letter code in 
H77
Resistant amino 
acid
282 S S Ser T
316 C C Cys Y/N
365 S S Ser ?
368 S S Ser T
395 A A Ala G
411 N N Asn S
414 M M Met T
419 L L Leu S
421 A A Ala V
422 R R Arg K
423 M M Met V/T
444 N N Asn K
445 C C Cys F/N/G
448 Y Y Tyr H/C
451 C C Cys S/R
482 I I Ile L
486 A A Ala V
494 V V Val ?
495 P P Pro S/L
496 P P Pro ?
499 V A Ala ?
553 A A Ala V
556 S S Ser F/N/G
559 D D Asp G
565 S S Ser F
585 I I Ile V
Table S3 lists the known DAA resistance associated mutations in NS5b which was assessed in this study.
table s4. Variant detection cut-off 
Depth Frequency
50x 10%
100x 5%
200x 2.5%
400x 2%
>1000x 1%
Sequence read depth cut-off used for variant detection with a minimum count of five independent reads.  
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table s6. DAA resistance associated mutations found in patients with poor treatment outcome
Sample ID Gene Amino acid change Frequency (%)
Ad04 baseline NS3/NS4a none
NS5a Met28Val 85.0
NS5b Ala421Val 96.3
NS5b Ile482Leu 98.6
NS5b Met414Thr 97.2
Ad04 week 4 NS3/NS4a none
NS5a
NS5b Ala421Val 99.8
NS5b Il482Leu 99.8
NS5b Met414Thr 99.5
NS5b Cys445Phe 97.0
NS5b Ala553Val 99.8
On14 baseline NS3/NS4a none
NS5a
NS5b
On14 week 4 NS3/NS4a Thr54Ala 53.6
NS3/NS4a Arg155Lys 14.0
NS5a none
NS5b
Patient Ad04 and On14 were sampled at baseline and after four weeks of treatment. Known direct acting 
antiviral resistance associated substitutions were assessed at both sampling points and the variant 
frequencies were identified from the sequence data.  
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abstr act
Introduction 
Mucosal-associated invariant T (MAIT) cells comprise a subpopulation of T cells that 
can be activated by bacterial products and cytokines to produce IFN-γ. Since little is 
known on MAIT cells during HCV infection, we compared their phenotype and func-
tion in comparison to HIV and HCV/HIV co-infected patients, and determined the ef-
fect of IFN-α-based and direct-acting antiviral therapy on MAIT cells of HCV patients. 
Methods
Blood samples from patients with chronic HCV (CHCV), virologically suppressed HIV, 
acute HCV/HIV co-infection (AHCV/HIV) and healthy individuals were examined by 
flowcytometry for phenotype and function of MAIT and NK cells. 
Results
Compared to healthy individuals, the frequency of CD161+Vα7.2+ MAIT cells was 
significantly decreased in patients with CHCV, HIV and AHCV/HIV co-infection. CD38 
expression on MAIT cells was increased in AHCV/HIV patients. MAIT cells were re-
sponsive to IFN-α in vitro as evidenced by enhanced frequencies of IFN-γ producing 
cells. IFN-α-based therapy for CHCV decreased the frequency of IFN-γ+ MAIT cells, 
which was still observed 24 weeks after successful therapy. Importantly, even after 
successful IFN-α-based as well as IFN-α-free therapy for CHCV, decreased frequencies 
of MAIT cells persisted. We show that the frequencies of MAIT cells are reduced in 
blood of patients with CHCV, HIV and in AHCV/HIV co-infection compared to healthy 
individuals. Successful therapy for CHCV did not normalize MAIT cell frequencies at 
24 weeks follow up.
Conclusion
The impact of HIV and HCV infection on the numbers and function of MAIT cells war-
rant further studies on the impact of viral infections and the antimicrobial function 
of MAIT cells. 
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introduction
Following infection with hepatitis C virus (HCV), hepatocytes are triggered to produce 
type I and III interferons (IFN), which induce the expression of hundreds of IFN stimu-
lating genes (ISG) with anti-viral activity (210-212). However, despite the induction of 
ISG, viral titers increase during acute HCV infection, and in the majority of infected 
individuals the virus is able to establish a chronic infection of the liver, which indi-
cates that the immune response is ineffective (213, 214). Besides the induction of ISG, 
IFN also activates natural killer (NK) cells, T cells and dendritic cells (DCs), and are 
therefore important immunomodulators (211, 215-218). Similar as in HCV, type I IFN 
are produced in large amounts after infection with human immunodeficiency virus 
(HIV), causing induction of antiviral responses that target every step of the HIV life 
cycle (218). 
In recent years, our understanding of Mucosal-Associated Invariant T (MAIT) cells in 
chronic HIV infection has increased substantially. Most MAIT cells are CD8+ or double 
negative for CD4 and CD8, and characterized by the expression of CD161 and the 
invariant T cell receptor (TCR) Vα7.2 that recognizes vitamin metabolites presented 
by MR1, a MHC class I related protein, on the surface of antigen-presenting cells (219, 
220). MAIT cells are also activated by IL-12 and IL-18 in an MR1-independent manner 
(221). MAIT cells are abundant in human blood (1-10% of CD8+ T cells) and are known 
for their antimicrobial activity to bacteria and yeast in the gut and lungs (222, 223) 
via release of cytokines and cytotoxic enzymes (219). Interestingly, MAIT cells are 
reduced in peripheral blood and lymph nodes of patients with chronic HIV infection, 
and their cytokine production and cytolytic functions are severely affected which has 
been suggested to be the result of exhaustion. Importantly, the loss and dysfunction 
of MAIT cells are not recovered after successful combination antiretroviral therapy 
(cART) therapy (224-231). It has been suggested that the functional impairment and 
numerical decline of MAIT cells contributes to the high incidence of bacterial infec-
tions observed in HIV patients (227). At the moment it is unclear what causes the 
depletion of MAIT cells in HIV infection. Similar findings were reported recently in 
patients chronically infected with HCV where the MAIT cell numbers in blood were 
severely reduced during persistent infection (232). Also in chronic HCV, successful 
HCV clearance by IFN-free therapy does not result in normalization of MAIT cell 
numbers.
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Because little information is available on the role of MAIT cells in HCV infection, 
we examine in this study the impact of HCV infection on MAIT cells. In addition, we 
investigate the consequence of IFN-α exposure on NK cells and MAIT cells during 
IFN-α based therapy for CHCV and acute-HCV/HIV co-infection.
methods
Patients and healthy subjects 
Heparinized blood was collected from 33 patients with chronic HCV (CHCV) infection, 
9 acute HCV patients with cART-suppressed HIV (AHCV/HIV), 10 patients with cART-
suppressed HIV mono-infection and 12 healthy subjects. The patient characteristics 
are listed in table 1. 33 CHCV patients were treated in 4 different historical treatment 
regimens, and blood was collected at multiple time-points. In cohort 1, 11 patients 
were treated with pegylated-IFN-alpha-2a (PegIFN-α) and ribavirin for 24 or 48 weeks, 
according to HCV genotype (NCT00422838, (233)). Patients in cohort 2 (n=11) were 
treated with telaprevir, PegIFN-α and ribavirin for 24 or 48 weeks, according to their 
fibrosis level and previous treatment response to PegIFN-α and ribavirin. Consistent 
with international guidelines (48), patients were treated with telaprevir, PegIFN-α and 
ribavirin for the first 12 weeks, and continued treatment consisting of PegIFN-α and 
ribavirin only (NCT01641094). In this treatment cohort, naïve patients, patients with a 
partial response (>2log drop in viral load) to previous IFN-based therapy, and patients 
without cirrhosis were treated for 24 weeks when HCV RNA was undetectable (<15 
IU/l) at week 4 and 12 during therapy. In cohort 3, 5 patients were treated with daily 
daclatasvir and twice daily asunaprevir for 24 weeks (NCT02282709, (234)). In cohort 
4, 6 patients were treated with sofosbuvir and daclatasvir with or without ribavirin 
for 12 or 24 weeks according to the international guidelines (AASLD/IDSA Recom-
mendations for testing, managing, and treating hepatitis C 2015 (hcvguidelines.
org) and EASL: recommendations on treatment of hepatitis C 2015). The selection of 
the treatment regimen was solely made by the treating physician. For patients with 
CHCV, blood was collected at baseline, week 4, week 12 during therapy and 24 weeks 
after end of therapy in all 4 cohorts. Patients with acute HCV and cART-suppressed 
HIV were treated in cohort 5 (n=9). Patients were treated within 26 weeks after HCV 
infection with 12-weeks boceprevir, PegIFN-α and ribavirin (NCT01912495). Blood was 
collected at baseline and at week 4 during therapy. Patients with cART-suppressed 
HIV mono-infection (n=10) and 22 healthy subjects (67% male, average age: 54 
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(range 42-70)) were included as controls. The institutional ethical review board of the 
Erasmus Medical Center approved the protocols, and written informed consent was 
obtained from all individuals. 
Analysis of cell surface molecule expression by flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from venous blood by (Fi-
coll-PaqueTM plus, Amersham) and frozen at -150°C. PBMC were thawed and washed 
with RPMI 1640 (Lonza) with 10% FCS (Lonza). For flow cytometry, 500,000 PBMC 
were used for each staining. Cells were stained with anti-CD38-PerCp-eFluor710 
(HB7), anti-CD3-PE-Cy7 (UCHT1), anti-CD161-Pacific Blue (HP-3G10, all eBiosciences), 
anti-CD4-APC-H7 (SK3, BD Biosciences), anti-TCR Vα7.2-PE (3C10, Biolegend), anti-
CD56-APC (N901, Beckman) and live/dead marker (Aqua, Life technologies) for 20 
minutes at 4°C in the dark. Positivity for CD38 was determined by setting the gates 
using internal negative cells. Cells were washed and marker expression was detected 
by flow cytometry (Canto-II, BD). MAIT cells were defined as CD3+CD161+Vα7.2+ cells 
within the lymphocyte gate and NK cells were defined as CD3-CD56+ cells within the 
lymphocyte gate. Data was analyzed using FlowJo version 10.1 (Tree Star Inc).
Analysis of intracellular cytokines by flow cytometry. 
The percentage of cells producing IFN-γ was measured by flowcytometry using vari-
ous stimuli. For each condition, 500,000 cells were stimulated in a 24 wells plate with 
IL-12 (0.25 ng/ml, Miltenyi), IL-18 (50 ng/ml, MBL) and IFN-α (2500 IU/ml, Intron-A, 
Merck). For all conditions, cells were stimulated for 16 hours at 37°C at 5% CO2. 
Brefeldin A (10 μg/ml, Sigma) was added and the cells were incubated for another 3 
hours. Cells were stained with anti-CD3-PerCp-Cy5.5 (UCHT1), anti-CD4-APC-H7 (SK3, 
both BD biosciences), anti-CD69-PE-Cy7 (TPI.55.3), anti-CD161-PB (HP-3G10, both 
eBiosciences), anti-TCR Vα7.2-PE (3C10, Biolegend), anti-CD56-APC (N901, Beckman) 
and Live/ dead marker (Aqua, Life technologies). Cells were fixed, permeabilized 
and stained with anti-IFN-γ-FITC (25723.11, BD Biosciences). Cytokine-producing cells 
were detected by flow cytometry (Canto-II, BD). Quadrants were set on low or absent 
expression on lineage negative cells. Data was analyzed using FlowJo version 10.1 
(Tree Star Inc).
statistics
Statistical comparison was tested using the Kruskal-Wallis and Mann-Whitney test 
for unpaired non-parametric analyses and the Paired student t-test for paired ob-
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servations. A p value ≤ 0.05 was considered significant. All data was analysed using 
GraphPad Prism (GraphPad Software).
results
mait cells are decreased in patients with chronic hcV, hiV and ahcV/hiV co-
infection compared to healthy controls. 
We investigated whether MAIT cells are affected during chronic viral infections and 
compared them to NK cells. For this purpose, the frequencies of CD3+CD161+Vα7.2+ 
MAIT cells and CD3-CD56+ NK cells were determined in peripheral blood of patients 
with CHCV, HIV, AHCV/HIV and healthy individuals by flow cytometry (figure 1A and 
1B). A significant decrease was observed in the frequencies of MAIT cells in CHCV, 
HIV and AHCV/HIV patients as compared to healthy controls (p=0.004, p=0.04 and 
p=0.01, respectively, figure 1B). No differences were observed in frequencies of NK 
cells in patients with AHCV/HIV co-infection compared to healthy controls (235-238), 
whereas NK cells in CHCV and HIV mono-infected patients were decreased compared 
to healthy controls (p=0.009 and p=0.003, respectively) (figure 1B). Next, we deter-
mined the expression of the activation marker CD38 on MAIT cells and observed that 
patients with AHCV/HIV co-infection had increased frequencies of activated MAIT 
cells in peripheral blood compared to HIV, CHCV and healthy individuals (p=0.01, 
p<0.001, p=0.002 respectively, figure 1B). No association between the frequency of 
MAIT cells and ALT levels (r-value: -0.185, p=0.42) or viral load (r-value: 0.019, p=0.93) 
was observed (figure 1C). Also, stratification of patients with CHCV of their fibrosis 
stage showed similar frequencies of MAIT cells (figure 1C). 
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figure 1: Frequencies of MAIT cells are decreased in patients with CHCV, HIV and AHCV/HIV co-
infections compared to healthy individuals.  (A) Representative dot plots and gating strategy of 
CD3+CD161+ Vα7.2+ MAIT cells and CD3-CD56+ NK cells. (B) The percentage of MAIT cells within the 
CD3+ T cell population, NK cells within the lymphocyte population, and CD38+MAIT cells within the total 
MAIT cell population of healthy individuals (n=22 for frequencies of MAIT and NK cells; n=12 for fre-
quencies of CD38+ MAIT cells), chronic HCV (CHCV) patients (n=33), cART-suppressed HIV (HIV) patients 
(n=10) and patients with acute HCV/HIV co-infection (AHCV/HIV)  (n=9). (C) Frequency of MAIT cells with-
in the CD3+ T cell population in CHCV patients do not correlate with ALT, HCV RNA or fibrosis score levels. 
No association between the frequency of MAIT cells and ALT levels (r-value: -0.185, p=0.42) or viral load 
(r-value: 0.019, p=0.93) was observed. Statistical comparison was tested using Mann-Whitney test for 
unpaired analyses. Spearman’s correlation test was used for the first two panels of figure 1C.
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figure 2: MAIT cells function does not differ between patients with chronic HCV, HIV and AHCV/HIV co-
infection. (A) Representative dot plots of CD69 expression and IFN-γ production by MAIT and NK cells in 
CHCV after stimulation with IL-12/IL-18. (B) Frequency of CD69 expression and IFN-γ producing MAIT 
cells and NK cells in CHCV patients after 19 hours stimulation with medium, IL-12/IL-18 and IFN-α/IL-18. 
(C) Frequency of IFN-γ producing MAIT cells after various stimuli between healthy individuals, patients 
with CHCV, HIV and AHCV/HIV co-infection. Statistical comparison was tested using paired T test (2B) and 
Mann-Whitney test (2C).
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frequency of il12/il-18 induced ifn-y producing mait cells does not 
differ between patients with CHCV, HIV, AHCV/HIV co-infection or healthy 
individuals. 
Next, we determined the ability of MAIT cells from the various patient groups to 
respond to IL-12/18 as well as to IFN-α/IL-18 and evaluated CD69 surface expres-
sion and production of IFN-γ. A representative dot plot and gating strategy after 
stimulation of CHCV peripheral blood with IL-12/18 is shown in figure 2A. As shown 
in figure 2B, CD69 expression on both MAIT cells and NK cells was upregulated upon 
stimulation with IL-12/18 and IFN-α/IL-18, as compared to medium control conditions. 
The frequency of IFN-γ producing MAIT cells was significantly increased upon stimu-
lation with IL-12/18. Importantly, IFN-α was also found to be a potent activator of 
MAIT cells (figure 2B). Next, we determined the function of MAIT cells in different viral 
infections and observed that MAIT cells are equally capable to become activated and 
produce IFN-γ upon stimulation with IL-12/18 and IFN-α/IL-18 in CHCV, HIV, AHCV/HIV 
co-infection and healthy individuals (figure 2C). 
ifn-based therapy for chronic hcV reduces the frequency of ifn-γ producing 
mait cells upon il-12/il-18 stimulation.
Figure 2B shows that IFN-α is a potent stimulator of MAIT cells in vitro. Since IFN-α has 
potent antiviral activity against HCV, we determined whether IFN-α-based therapy for 
CHCV activates MAIT cells and affects MAIT cell frequencies in CHCV and AHCV/HIV co-
infection. Twenty-two CHCV patients were treated with IFN-based therapy with (n=11) 
or without (n=11) telaprevir. All patients were HCV RNA negative at week 12 during 
therapy. We observed that IFN-α-based therapy did not alter MAIT cell frequencies, 
but did increase CD38 expression on MAIT cells (p<0.001, figure 3A, upper panels). 
No difference was observed between treatment with or without addition of telaprevir 
(supplementary figure 1). The NK cell frequency was reduced early during IFN-based 
therapy (p<0.001), but this was not sustained at week 12 (figure 3A, upper panels). 
Recently, IFN-free therapy became available for clinical use and has substituted IFN-
α-based therapy because of higher SVR rates and reduced side-effects. Eleven CHCV 
patients were treated with an IFN-free regimen and we determined if the observed 
effects on MAIT cells were due to a direct effect of IFN-α or to viral load decline. In 
all patients, HCV RNA titers were undetectable after 4 weeks of treatment; however, 
no effect was observed on MAIT cell frequency or activation (figure 3A, middle row). 
In addition, no effect was observed on NK cell frequencies (figure 3A, middle panels). 
These data suggest that the increased frequencies of CD38-expressing MAIT cells 
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figure 3: IFN-based therapy for chronic HCV increases expression of CD38 on MAIT cell but reduces MAIT 
cell function. (A) Frequency of MAIT, CD38+MAIT cells and NK cells during IFN-based therapy for CHCV 
(cohorts 1 and 2, n=22), IFN-free therapy for CHCV (cohort 3 and 4, n=11) and IFN-based therapy for 
AHCV/HIV co-infection (cohort 5, n=9). At week 12 during therapy for CHCV and at week 4 during therapy 
for AHCV/HIV, all patients were HCV RNA negative. (B) Frequency of IFN-γ producing MAIT cells after stim-
ulation with IL-12/18, and medium during IFN-based and IFN-free therapy for CHCV infection (baseline, 
4wk, 12wk), and during IFN-based therapy for AHCV/HIV (baseline, 4wk). The baseline frequencies of 
CD38+ MAIT cells and IFN-γ+ MAIT cells of the patient groups receiving IFN-based and IFN-free therapy 
were similar (Mann Whitney test). All other statistical comparisons were tested using Wilcoxon matched 
pairs T test. 
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in CHCV patients is the consequence of exposure to IFN-α, rather than of viral load 
decline.
Patients with AHCV/HIV co-infection were treated with a combination of boceprevir, 
PegIFN-α and ribavirin; all patients were HCV RNA negative at week 4 during therapy. 
IFN-α-based therapy did not alter MAIT cell or NK cell frequencies in this patient 
population (figure 3A, lower panels). The enhanced expression of CD38 on MAIT cells 
of patients with AHCV/HIV co-infection (figure 1) was not further increased during 
therapy (figure 3A, lower panels). 
To investigate whether MAIT cell function was altered during therapy for HCV, cells 
were stimulated with IL-12/18. Surprisingly, although IFN-α-based therapy for CHCV 
caused increased expression of activation marker CD38 on MAIT cells as shown in 
figure 3A, a decrease in the frequency of IFN-y producing MAIT cells was observed 
upon stimulation with IL-12/18 during therapy compared to medium (p=0.02 at week 
4, p=0.03 at weeks 12; figure 3B, upper panels). Neither in CHCV patients treated 
with IFN-free therapy, nor in patients with AHCV/HIV co-infection, therapy altered 
the frequencies of IFN-γ producing MAIT cells (figure 3B, middle and lower panels).
successful therapy for chronic hcV does not restore mait cell frequency 24 
weeks after therapy.
Besides evaluation of the effect of therapy on phenotype and function of MAIT cells, 
it is highly relevant to determine the effect of viral clearance. Blood was collected 24 
weeks after end of therapy. No samples from patients with AHCV/HIV co-infection 
were available after therapy. Figure 4 shows that 24 weeks after cessation of IFN-
based therapy as well as IFN-free therapy, the MAIT cell frequencies were not restored 
in CHCV patients and remained low (figure 4, upper panels). The increased expres-
sion of CD38 on MAIT cells during IFN-based therapy for CHCV (figure 3A) was not 
maintained 24 weeks after therapy and returned to pre-treatment levels (figure 4). 
Interestingly, the suppressive effect of IFN-based therapy on IFN-y producing MAIT 
cells as shown in figure 3, was still observed 24 weeks after cessation of therapy 
upon IL-12/IL-18 stimulation (p=0.002, figure 4). Therefore, it appears that IFN-based 
therapy for CHCV affects IFN-y producing MAIT cells at least up to 24 weeks after 
therapy. No differences in frequencies of MAIT cells, CD38+ MAIT cells or IFN-γ 
producing MAIT cells were observed before and 24 weeks after IFN-free therapy for 
CHCV (figure 4, right panels). 
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discussion 
In this study we performed a detailed analysis on MAIT cells in CHCV, HIV and AHCV/
HIV infections. We observed that the frequency of MAIT cells is decreased in all three 
groups of infected patients compared to healthy individuals, and that no normaliza-
tion was observed following successful anti-HCV therapy at a follow-up period of 
24 weeks. Moreover, the frequency of IFN-y producing MAIT cells upon IL-12/IL-18 
stimulation was reduced in blood from HCV patients receiving IFN-α-based therapy, 
but not in blood from patients receiving IFN-free therapy. 
Our findings on reduced MAIT cell frequencies in HIV and HCV are in line with others 
(224-227, 239). We confirmed the recent study by Hengst et al. (23) by showing reduced 
frequencies of CD161+Vα7.2+MAIT cells in peripheral blood of CHCV patients, long 
after viral clearance. From our studies, we cannot conclude whether the reduced fre-
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fig. 4. Frequency of MAIT cells in peripheral blood of chronic HCV patients does not recover after success-
ful therapy. Frequencies of MAIT, CD38+MAIT and IFN-γ+ MAIT cells before and 24 weeks after successful 
IFN-based (left, n=22) and IFN-free (right, n=9) therapy for CHCV. Frequencies of IFN-γ+ MAIT cells were 
measured after 19 hours stimulation with IL-12/18. Statistical comparison was tested using Wilcoxon 
matched pairs T test.
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quencies of MAIT cells are due to depletion of cells via apoptosis, migration of MAIT 
cells from blood to peripheral organs or skin, or due to down-regulation of charac-
teristic markers, such as CD161. However, others have demonstrated that it is unlikely 
that CD161 down-regulation is responsible for the observed MAIT cell numbers in HIV 
infection (19). In addition, it has been shown that MAIT cells are systemically depleted 
in simian immunodeficiency virus infected rhesus macaques, a model often used to 
investigate HIV (240). This suggests that migration of MAIT cells to peripheral organs 
in HIV is less likely. More research is needed to clarify the cause of the depletion 
in HIV and HCV. Importantly, virus eradication by IFN-based therapy as well as by 
IFN-free therapy did not lead to normalization of the reduced MAIT cell frequencies 
at 24 weeks after cessation of therapy. These findings are similar to the observations 
by Hengst et al. who showed nonreversible MAIT dysfunction 48 weeks after end of 
treatment with sofosbuvir and ribavirin (23). The long-term complications of low MAIT 
cell frequencies may be an increased susceptibility of bacterial infections after viral 
clearance. These observations are reminiscent of the findings reported in HIV where 
long-term suppression of viral replication by cART does not result in normalization 
of MAIT numbers in blood (224, 226, 227). It is well-known that the immune system 
in cART-controlled HIV patients remains at a higher activation status as compared 
to control healthy individuals, but it is unknown whether the enhanced immune 
activation mediates MAIT cell depletion. Besides a lower frequency of MAIT cells, we 
also observed a lower frequency of NK cells in HIV patients compared to CHCV and 
healthy individuals (p=0.02 and p=0.02). Decreased NK cell frequencies and func-
tion in HIV patients has been described before to be associated with a more rapid 
progression to AIDS in untreated patients (241). 
Besides their numbers, the function of MAIT cells is also an important determinant of 
their contribution to the overall response to HIV or HCV. As shown in this manuscript 
and reported by others, MAIT cells are highly responsive to IL-12/IL-18 (221, 225). We 
now show that MAIT cells are also responsive to the combination of IFN-α and IL-18, 
leading to the production of IFN-γ. The ability of MAIT cells to respond to IFN-α is 
shared with NK cells. 
The function of MAIT cells, as reflected by the frequency of IFN-y producing MAIT 
cells upon IL-12/IL-18 stimulation was similar in patients with CHCV, HIV or AHCV/HIV 
as compared to healthy individuals. Recently, dysfunctional MAIT cells from chronic 
HCV patients with respect to their ability to produce IFN-γ were observed upon MR1-
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dependent antigen stimulation, but -similar to our findings- not upon IL-12/IL-18 
stimulation (23). However, since MAIT cells are decreased in these patients groups, the 
total amount of IFN-y by these MAIT cells is likely to be decreased. Also the activation 
state of MAIT cells from CHCV and HIV patients were not affected. In contrast, MAIT 
cells from AHCV/HIV patients exhibited higher frequencies of CD38-expressing MAIT 
cells, which may be the result of exposure to pro-inflammatory serum cytokines that 
are known to be present at relatively high levels during acute HCV infection (242). 
Viral load reduction by DAA-therapy in CHCV patients did not affect MAIT cell activa-
tion or IFN-γ+ frequencies, whereas IFN-based therapy strongly affected both param-
eters. We observed that IFN-based therapy enhanced the expression of the activation 
marker CD38 on MAIT cells, but decreased the frequencies of IFN-y producing MAIT 
cells. Since the activation state of MAIT cells during IFN-based therapy is augmented, 
it is unlikely that the effect on IFN-y production is the result of an overall inhibitory 
effect on the MAIT cells, but it may be the consequence of functional paralysis due 
to prolonged exposure to IFN-α. Although highly speculative, this may also explain 
the opposing effects of IFN-α on the frequencies of IFN-y producing MAIT cells upon 
short-term exposure in vitro and long-term exposure in vivo. The observation that 
IFN-based therapy, but not DAA-therapy, suppresses the functionality of MAIT cells, 
may indicate that a disadvantage of IFN-based-therapy over DAA therapy is that it 
affects the anti-microbial function of MAIT cells and that the reduced functionality of 
MAIT cells may render individuals more susceptible to pathogens. 
In conclusion, we show that MAIT cells are decreased in patients with chronic HCV, 
HIV and AHCV/HIV co-infection compared to healthy controls. We show that IFN-α 
modulates MAIT cells in vitro, and in vivo during IFN-based therapy for HCV but 
importantly, a sustained viral response for HCV does not rescue MAIT cell frequency. 
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supplementary figure 1: No clear differences are observed between CHCV patients treated with IFN/
based therapy with or without telaprevir. Patients with CHCV were treated with peginterferon and riba-
virin alone (n=9) or in combination with telaprevir for 12 weeks (n=11). All patients were responsive to 
either treatment and were HCV RNA negative at week 12 of therapy (<15 U/ml). Frequencies of MAIT, 
CD38+MAIT and NK cells before and 12 weeks during therapy are shown.
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The first phase of a hepatitis C virus (HCV) infection, in this thesis named acute 
HCV, has a certain intangibility. This phase clearly starts with the transmission of the 
virus. The exact time-point however, is rarely known because of multiple potential 
exposures in risk groups. Thereby, the end of an acute infection remains undefined 
as well. At the moment, there is no clear marker that identifies the end of the acute 
and beginning of the chronic stage of infection. This results in different perspectives 
on acute HCV from epidemiological, virological, immunological and clinical points of 
view and complicates the research field. These perspectives need to be kept in mind 
when reading the following discussion and give some guidance through the summary 
of the different chapters. 
Generally, it is believed that the use of HCV RNA amplification with retrospective 
negative testing is the most accurate way of diagnosing an acute HCV infection. In 
the Netherlands, samples of patients in HIV-care are systematically stored, so ret-
rospective testing is easily performed. This policy makes it possible to diagnose a 
HCV infection in the acute stage with very high certainty. In chapter 2, we describe 
the results of a system based on voluntary reporting of acute HCV infections by HIV 
treating physicians. In 2014, a total number of 99 newly diagnosed HCV infections 
were reported in 19 HIV treatment centers. This resulted in a mean incidence rate of 
11/1000 person years of follow-up in HIV positive men having sex with men (MSM). 
Most of them (78%) were diagnosed through HCV RNA amplification with retrospec-
tive negative testing. This study, based on voluntarily reporting, was successful 
because the concurrent Dutch Acute Hepatitis C in HIV Study (DAHHS) created aware-
ness among physicians, nurses and patients on the importance of diagnosing HCV in 
the acute stage. When diagnosed with an acute HCV infection, participation in the 
DAHH-Study allowed for a 50% shorter treatment duration. The study in chapter 2 
provides some additional interesting insights on the characteristics of the Dutch HCV 
epidemic. First, the incidence rate we found was very comparable to the observed 
incidence in other national and international studies (34, 156). Remarkably, despite 
the fact that acute HCV is one of the infectious diseases that physicians are obliged 
to report to the National Institute for Public Health and the Environment (RIVM), the 
RIVM reported only 30 infections in 2014 (24). This indicates that the current method 
of surveillance on the incidence of HCV infections is inadequate and therefore the 
magnitude of the epidemic underestimated. Second, before the results of this study 
became available, acute HCV infections were considered to be rather limited to ‘big 
cities’ like Amsterdam and Rotterdam. In chapter 2, we show that in more than 50% 
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of the 19 participating Dutch hospitals the incidence of HCV was above 8.7/1000 
patient years of follow up. So, it is fair to conclude that transmission of HCV among 
HIV positive MSM is a nationwide problem. Also in 2015 the epidemic continued, 
which was nicely illustrated by a reported outbreak in a city in a rural area named 
Enschede (254). Last but not least, we confirmed that the number of HCV reinfections 
was very high, as 25% of the patients with an acute HCV infection in 2014 had been 
cured from a previous infection. The high incidence rates of reinfection have been 
previously reported and our study confirms these findings (37, 38). Therefore, the 
alarming rate of reinfections should be of special concern to physicians. Patients 
with their first HCV infection should be counseled thoroughly about their, potentially, 
ongoing high risk behavior. 
When an acute HCV infection is studied from a virological point of view, a dynamic 
pattern of HCV plasma viral loads is the hallmark of a recently acquired infection. After 
intravenous transmission, HCV is detectable in peripheral blood within 2 weeks(255). 
When an acute HCV infection is diagnosed, three patterns of HCV kinetics can be 
distinguished: spontaneous clearance, plateau viremia or fluctuating viremia (53, 
58). These patterns, which are discussed in chapter 1, can be detected with HCV 
RNA measurements in plasma. HCV RNA amplification by polymerase chain reaction 
(PCR) is, however, a precise but expensive method to observe these patterns (256). 
Therefore, equally reliable and cheaper tests are required to diagnose and monitor 
acute HCV infections in the acute stage of the disease. In chapter 3, we study the 
clinical use of HCV antigen (Ag) testing for diagnosing acute HCV infections and to 
evaluate the response in patients treated in the DAHH-Study. HCV Ag proved to be a 
very accurate method to diagnose chronic HCV infections (131, 257). Also during the 
acute stage of disease, we could conclude that HCV Ag has a good correlation with 
HCV RNA. However, in 5 out of 44 patients with very low HCV RNA loads (<2200 IU/
ml), HCV Ag was not detectable. Compared to HCV RNA as the golden standard, the 
sensitivity and specificity of HCV Ag testing were 89% and 100%. These results were 
similar to another study performed in a comparable British patient population(129). 
Therefore HCV Ag seems to be a reasonable alternative for HCV RNA testing to 
diagnose an acute HCV infection. Unfortunately, we were unable to study the kinet-
ics of HCV Ag in patients with different HCV RNA kinetics during the acute stage of 
infection because the DAHH-Study was not designed to study the natural course of 
an acute HCV infection.
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Apart from the detectability of HCV RNA and HCV Ag, IgG seroconversion is another 
hallmark of an acute HCV infection. Unfortunately, IgM testing, which is often used 
to diagnose infections in the acute stage, is not an adequate marker for acute HCV 
infections (258). IgG seroconversion can be diagnosed in the acute stage if there are 
preceding negative test results. If no previous test result is available, the combina-
tion of a negative IgG antibody with HCV RNA positivity resembles the incomplete 
immune response which is characteristic for an acute infection. A study by Thomson 
and colleagues among HIV infected patients with acute HCV showed that IgG sero-
conversion occurs mostly within 6 months up to one year after acute HCV diagno-
sis(49). These results suggest that an acute HCV infection, especially in HIV infected 
patients, will often be missed when relying on seroconversion. Therefore, as PCR 
is available, seroconversion is not frequently used as the only marker to diagnose 
acute HCV infections in the Netherlands. Remarkably, as shown in chapter 3, 91% of 
the patients included in the DAHHS compared to 63% of the patients described by 
Thomson and colleagues seroconverted within 4 months after calculated transmis-
sion. These discordant results could be explained by slight differences in anti-HCV 
testing methods and CD4+ T-cell counts. Altogether, these findings suggest that HCV 
IgGseroconversion could be, besides HCV RNA and HCV Ag, an adequate marker for 
diagnosing an acute infection. This is especially relevant when prices and practi-
cability of these diagnostic tests are compared: HCV antibody testing is easier and 
significantly cheaper than HCV RNA amplification.
From a clinical perspective, the definition of an acute infection is maybe debated 
the most. Because the natural presentation of an acute HCV infection is associated 
with few clinical symptoms, physicians have to rely on laboratory testing(133, 259). 
Besides the differences in the nomenclature of acute HCV infections (recently 
acquired HCV infection, new HCV infection or early HCV infection) there is also a 
broad spectrum of definitions used in studies on acute HCV. In a systematic review 
by Hajarizadeh and colleagues, 169 studies were compared on the definition of acute 
HCV infections(47). These studies covered epidemiological, biological and clinical 
definitions. In 32,5% of the studies, HCV seroconversion was the only criterion for 
the definition acute HCV. Other frequently used definitions were: seroconversion 
combined with HCV RNA positivity and alanine aminotransferase elevation (14,8%) 
or HCV RNA detectability with being antibody negative (13,6%). The major point 
stated by the authors is therefore that more standardized case definitions are neces-
sary. 
152 Chapter 10
The DAHH-Study, presented in chapter 4, used a very strict definition of acute HCV: 
treatment within 26 weeks after the calculated transmission date. We defined ‘cal-
culated transmission date’ as the exact midpoint between the last negative and the 
first positive sign of hepatitis in blood. In the DAHH-Study, patients were treated with 
boceprevir, pegIFN and ribavirin during 12 weeks. Boceprevir is a first generation 
NS3a/4 protease inhibitor and was, together with telaprevir, the first direct act-
ing antiviral (DAA) registered for the treatment of chronic HCV genotype 1 in the 
Netherlands in 2012. In the primary endpoint analysis we showed a 100% sustained 
virological response (SVR) rate in patients with a rapid virological response, which 
is defined as an undetectable HCV RNA at week 4 of therapy. This so-called rapid 
virological response is a well-defined predictor of treatment success in acute and in 
chronic HCV infected patients receiving pegIFN-based therapy (98, 133, 137, 260). 
We proved that also during boceprevir, pegIFN and ribavirin therapy for acute HCV, 
a rapid virological response is a very reliable predictor of treatment success. Ad-
ditionally, the SVR rate in the intention-to-treat group was 86%. In comparison with 
a historical Dutch cohort of patients that received 24 weeks of pegIFN and ribavirin, 
the SVR rate was very comparable (86% and 84% respectively). 
If we compare the cure rates in the DAHH-Study to previously published studies in 
which patients were treated with pegIFN with or without ribavirin for 24 weeks, the 
cure rates in the DAHH-Study were substantially higher. In a review by Rockstroh 
on behalf of the European AIDS Treatment Network, a composite cure rate of 65% 
was found within HIV positive patients with an acute HCV infection (95). However, 
we consider the comparison with the Dutch historical cohort the more appropriate 
one as these controls were treated in the same centers as in the DAHH-Study and 
had very comparable baseline characteristics. The high cure rates in the DAHH-Study 
in comparison with the literature may be partially explained by selection bias, be-
cause the patients that opted-in for study participation could have been the most 
motivated ones. Another reason could lie in the definition of acute HCV infection, 
which was very strict. This made the accidental inclusion of patients with a previously 
undiagnosed chronic HCV infection and therefore a much lower chance of treatment 
success, impossible. 
Prior to the DAHH-Study, the efficacy of shortened treatment with a first generation 
DAA in combination with pegIFN and ribavirin had only been studied once in a small 
pilot study by Fierer and colleagues (115). They treated 19 acute HCV HIV-coinfected 
Summarizing discussion 153
10
patients with telaprevir, pegIFN and ribavirin for 12 weeks and cured 16 patients. So, 
in comparison with the DAHH-Study, this cure rate was very similar. Soon after comple-
tion of the DAHH-Study, several small pilot studies were presented with newer DAA 
combinations for the treatment of acute HCV. Recently, we described a case series 
of six acutely HCV genotype 4 infected patients treated with pegIFN, ribavirin and 
simeprevir. In this study we showed that all patients were treated successfully with 
12-16 weeks of triple therapy. Also other groups have presented pilot studies with 
combinations of the NS5b inhibitor sofosbuvir with ribavirin or sofosbuvir combined 
with a NS3a/4 or NS5a inhibitor. Remarkably, the cure rates varied substantially from 
32% to 100%. In two studies, the combination of sofosbuvir and ribavirin when given 
for 12 weeks was tested and resulted in cure rates of 59% (10/17) and 92% (11/12) 
respectively (143, 261). When given for 6 weeks, the combination of sofosbuvir and 
ribavirin was even less effective with a cure rate of 32% (6/19)(144). Combinations 
of sofosbuvir with ledipasvir (4 weeks) or simeprevir (8 weeks) in patients with acute 
HCV mono-infections seem to be much more promising with response rates of 93% 
(13/14) and 93% (13/15) respectively (145). However, in HIV coinfected patients 
the cure rate of 6 weeks sofosbuvir and ledipasvir was 85% (22/26) or even 77% 
(20/26) when two patients who were lost to follow-up are considered failures(262). 
In conclusion, also in acute HCV, the combination of DAAs seems to be very effective 
as well. However, the preferred combination and duration remains to be defined. 
Following the success of the DAHH-Study in the Netherlands, we initiated a new 
study: the DAHHS-2. In this study we test the efficacy and tolerability of a combina-
tion of the NS3a inhibitor grazoprevir and NS5a inhibitor elbasvir in 80 acute HCV 
HIV-coinfected patients (NCT02600325). This combination was shown to be effective 
when given for 12 weeks to patients with chronic HCV genotype 1 and 4. Therefore 
both genotypes will be treated in the DAHHS-2. This also means that we are able 
to treat almost all acute HCV infected patients, because, as described in chapter 2, 
genotype 1 and 4 are by far the most dominant genotypes in the Dutch population. 
The choice for the treatment duration of 8 weeks is based on the assumption that 
acute HCV can still be treated with shorter duration regimens, even when pegIFN-
free regimens are used. However in the light of the results of the previous pilot 
studies presented above, 8 weeks of treatment could be the minimum duration in 
HIV coinfected patients with an acute HCV infection. Another difference between the 
DAHHS 1 and 2 is that also patients from Belgium can be treated in a single center in 
Antwerp. Because the reimbursement of DAAs in Belgium is more stringent than the 
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Dutch reimbursement policy, we expect that a substantial part of the patients will 
be included in Belgium to prevent their acute HCV infection from becoming chronic. 
Another difference with DAHHS-1 is that also acute HCV mono-infected patients can 
be treated in the DAHHS-2. Recently, pre-exposure prophylaxis (PREP) studies have 
reported HCV infections in HIV-negative participants (263). This raised the concern 
that HCV is transmitted also between HIV negative MSM. Because sexual transmis-
sion of HCV between HIV negative MSM is probably rare, part of the transmissions 
may be the result of the intravenous use of chemicals (“party drugs”) like crystal 
meth, ketamine or mephedrone. This so-called ‘slamming’ is a recent trend entering 
the gay scene and has been associated with a rise in HIV and HCV infections (264).
During combination antiretroviral therapy (cART), special attention should be given 
to potential drug-drug interactions with concomitantly prescribed or non-prescribed 
medication. We studied the interaction between rilpivirine, a component of certain 
cART regimens given to patients with HIV, and boceprevir in chapter 5. Because 
boceprevir is a CYP3a inhibitor and rilpivirine a CYP3a substrate, this could result in 
increased plasma rilpivirine levels. During dose-finding studies with rilpivirine, it was 
found that increased plasma rilpivirine levels resulted in QT interval prolongation on 
the electrocardiogram, which are associated with cardiac arrhythmias(265). In this 
DAHHS sub-study we found a significant increase in rilpivirine plasma concentra-
tions in patients treated with boceprevir, without significant QT-prolongation on the 
electrocardiogram. The increase in rilpivirine AUC0-24h (71%) found in this study was 
higher than described in healthy volunteers (39%)(146). Therefore, we conclude that 
healthy volunteer data should be translated cautiously to HIV infected patients.
Maybe the most important question that arose after the DAHH-Study was completed 
is whether there is still a role for pegIFN based treatment options in patients with an 
acute HCV infection. Although high cure rates can be obtained with pegIFN based 
therapy in the acute stage of the disease, it is associated with significant side effects. 
Flu like symptoms, anemia and depressive symptoms are common pegIFN induced 
side effects. They result in a decrease in the quality of life and productivity during 
and sometimes also persist after the end of therapy (chapter 4). Therefore, also acute 
HCV infected patients could benefit from pegIFN free treatment if the same cure 
rates are obtained during acute HCV therapy as seen in chronically HCV infected 
patients. Unfortunately, the availability and reimbursement of sofosbuvir-based 
therapies remains limited in parts of the resource rich as well as resource limited 
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countries. In the USA, Medicaid programs in some states denied nearly half of all 
claims (46%) for treatment with DAAs in the chronic stage. Denials were significantly 
more common in patients who did not have signs of cirrhosis, which per-definition is 
the case in patients with acute HCV (266). In conclusion, as long as reimbursement 
issues continue, a short-course of a DAA with pegIFN and ribavirin may be a valid 
option for patients with an acute HCV infection.
In chapter 6 we modelled the effects on the epidemic of treating all acute and chronic 
HCV infected patients with a multiple DAA regimen with 89-100% cure. We compared 
this ‘immediate treatment’ to ‘delayed’ treatment with DAAs. Delayed treatment was 
defined as 24 weeks of pegIFN based treatment of acute HCV with a cure rate of 
52%-84%. If treatment fails, a pegIFN-free DAA regimen is given at METAVIR F2 or F3 
fibrosis. This model was based on the reimbursement policies of the Dutch Ministry 
of Health in 2014/2015. The limited reimbursement had to do with the extremely 
high therapy costs. In 2014/2015, a 12 week regimen of multiple DAAs was priced 
somewhere between 40.000 and 80.000 euro(267). The policy to delay treatment is 
based on the assumption that a chronic HCV infection is asymptomatic and results in 
limited morbidity until stage of F2 or F3 fibrosis and therefore does not need to be 
treated immediately. Treatment can therefore be delayed and, theoretically, costs can 
be saved because a substantial part of the infected population will never progress 
to F2 or F3 fibrosis(8). However, in models that have been presented or published, 
the effects of ongoing transmission from untreated infectious patients were not 
incorporated. In the study described in chapter 6, we therefore modelled the effects 
of different treatment approaches on the incidence and prevalence of HCV in the 
Netherlands. The main outcome was that immediate treatment of all HIV positive 
MSM with acute and chronic HCV did not result in elimination of the epidemic. The 
incidence declined from 12 to 4.2 per 1000 patients years and the prevalence from 
5% to 0.6% in 2055. These results were comparable to a study published by Martin 
and colleagues, who observed an even more substantial decline when behavioral in-
terventions were successfully implemented as well(184). However, at the moment, no 
intervention strategy has been proven to be effective in this population. Additionally, 
we calculated the extra costs and benefits of the immediate treatment policy until 
2055. Total additional costs were 29 million euro and benefits were 2596 quality 
adjusted life years. This resulted in an incremental cost- effectiveness ratio (ICER) of 
12.000 euro per quality adjusted life year. This ratio is particularly dependent on the 
price per DAA treatment. Given the fact that different new DAA regimens are upcom-
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ing, it can be expected that the price of DAA therapy will decrease substantially and 
the ICER as well. We conclude that, for the Netherlands, the impact of the immediate 
treatment policy on the epidemic is substantial, but that total elimination of HCV 
is not possible. Furthermore, the overall health budget impact is limited and DAA 
therapy was very cost-effective. 
The high effectiveness of DAAs led to statements that HCV can be eliminated on 
a worldwide scale. Several threats however can hamper global elimination. One of 
those could be the development of resistance against DAAs. Currently, almost all 
DAAs target the NS3/4a, NS5a or NS5b regions of the HCV genome. When patients 
fail DAA therapy, they mostly have mutations in the NS3/4a or NS5a region result-
ing in resistance to DAAs that target these regions (268). Polymorphisms in these 
genes can be present in a population as a naturally occurring variant or can be 
selected when a viral breakthrough or relapse of HCV is observed during or after 
DAA treatment. To determine the prevalence of resistance associated substitutions 
within patients treated in the DAHH-Study we performed resistance testing before 
and after treatment. The results are presented in chapter 7. In this study, whole HCV 
genomes were sequenced in collaboration with the PATHSEEK project. From 2012, 
boceprevir and telaprevir were used with limited success in chronically HCV infected 
patients. Therefore, we expected some baseline (pre-treatment) NS3/4a resistance in 
the DAHHS patient population with proven acquired HCV in 2013/2014. Fortunately, 
only in five patients a substitution in NS3/4a associated with low-level resistance 
to boceprevir or telaprevir was found before initiation of treatment. Because these 
mutations can also be found as a naturally occurring polymorphisms, they do not 
prove that transmitted drug resistance occurred(269, 270). The Q80K resistance as-
sociated variant in NS3/4a, however, was found in 40% of the baseline samples. This 
variant is not selected by boceprevir/telaprevir therapy but is a naturally occurring 
variant which results in resistance against simeprevir, another NS3/4a inhibitor. The 
prevalence of this variant is high in Europe, but low in some other parts of the world 
(e.g. Australia 4%) (202). Therefore, when no baseline resistance testing is performed, 
selection of DAA combinations seems to be dependent on the baseline prevalence 
of resistance associated variants in the geographic region where the patients were 
infected. Unfortunately, a significant amount of substitutions were found in the NS5a 
gene (M28V 22% and H58P 26%). These substitutions should be considered as 
naturally occurring variants as well, because NS5a inhibitors were not used in Europe 
before 2014 outside clinical trials. 
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In conclusion, it is unclear what the effect of resistant variants will be on the future 
HCV treatment. Patients with resistant variants will probably not benefit from short 
DAA combination therapies in acute and chronic HCV, but the exact role of the pres-
ence of resistant variants remains to be defined. As an example: recently, the FDA 
approved the combination tablet of grazoprevir and elbasvir for the treatment of 
HCV genotype 1 and 4. For genotype 1, the USA FDA favored the use of pre-treatment 
NS5a resistance testing. When resistant associated substitutions are detected at 
amino acid positions 28, 30, 31 or 93, treatment duration has to be increased to 16 
weeks and ribavirin added(207). In contrast, the Canadian prescription label does not 
recommend resistance testing. 
If a patient fails on DAA therapy, sequencing of specific parts of the HCV genome may 
be useful for two reasons. First, the difference has to be made between relapse and 
reinfection. As the rate of reinfection is high among HCV infected patients (chapter 
2), the ability to differentiate between sequential infections is necessary to monitor 
treatment response. This is illustrated by patient Ec03 in the DAHH-Study who pre-
sented 12 weeks after treatment with a new onset viremia. After genotyping by a Line 
Immuno Probe Assay, which showed a genotype 1a, one could conclude that the virus 
had relapsed. However, after whole genome sequencing of the virus from baseline 
and relapse, a genetically different 1a strain was detected and therefore the patient 
was considered to be re-infected with a new genotype 1a strain. The second reason 
to perform genome sequencing is to monitor the emergence of resistant variants. 
This may help in selecting the most appropriate second line treatment for patients. 
However, in most patients a DAA from a different class may be selected as the second 
line therapy without the need for genome sequencing. Of course, sequencing of a 
specific region instead of whole genome sequencing can be done to detect variants 
in the NS3/4a, NS5a or NS5b gene. 
Immunologically, one of the major challenges is to find a marker that clearly differ-
entiates between the acute and chronic stage of HCV and therefore, could be used to 
pinpoint acute infections in the individual patient. Because the response to IFN-based 
treatment is significantly different in the acute stage compared to the chronic stage 
of HCV, it is clinically important to differentiate between these phases when one 
would consider to treat a patient with pegIFN. The generally strong immune response 
against multiple epitopes during acute infection can be clearly distinguished from 
the weak, exhausted narrowly focused response during chronic infection. However, 
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there are no straightforward, simple and widely available laboratory tests that can 
differentiate an acute from a chronic infection and could be used in the clinic. This 
issue becomes even more complex in patients without an intact immune system like 
patients with a HIV coinfection or when patients were previously infected with HCV.
In chapter 8, we studied the impact of a HCV infection on mucosal-associated invari-
ant T (MAIT) cells. These cells comprise a subpopulation of T cells that are important 
for antimicrobial defense and can be activated by either the cytokines IL-12 and 
IL-18 or vitamin B metabolites (riboflavins) processed by bacteria. These vitamin B 
metabolites are presented by MHC class II related protein 1 (MR1) on antigen present-
ing cells (APC) to the invariant Valpha T cell receptor on the MAIT cell(271). MAIT cells 
seem to be reduced in peripheral blood of patients with a HIV infection and show 
signs of exhaustion in these patients (224). In a previous study, an inverse correlation 
between liver fibrosis and IL-17 dual expressing CD8+ T cells, a proxy for MAIT cells, 
was found(272). This suggests a role for MAIT cells in chronic liver diseases like HCV. 
As the role of MAIT cells in HCV infection was incompletely understood, we studied 
the functionality of these cells in different stages of a HCV infection. We found that 
MAIT cell frequencies were decreased in chronic HCV, HIV and acute HCV co-infected 
patients. After successful HCV treatment, no normalization of MAIT frequencies was 
observed in the chronic HCV infected patients. Additionally, we observed a significant 
difference between presence of activation markers (CD38) in MAIT cells between 
chronic and acute HCV infections. However, this state of increased activation was not 
in observed in interferon gamma production between MAIT cells of acute and chronic 
HCV infected patients after stimulation. 
The high expression of the activation marker CD38 in acute HCV infections could be 
the result of stimulation by high levels of cytokines and chemokines in the blood. 
These cytokines and chemokines could be used as biomarkers to detect an acute 
HCV infection and in the past, specific patterns of biomarker kinetics have been 
observed for acute HCV infections (242, 273). In chapter 9, we studied kinetics of 
several biomarkers in patients with HIV mono-infection and during their consecu-
tive HCV infections. First, we looked for differences between healthy volunteers, HIV 
mono-infected and HIV co-infected patients with an acute or chronic HCV infection. 
We observed, in general, that the biomarker levels were upregulated the most in 
acute HCV coinfected patients compared to others. This is in line with our expecta-
tions that the acute phase of a HCV infection results in the highest activation of the 
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immune system. Second, in 15 HIV infected patients with two consecutive acute HCV 
infections we tested biomarker kinetics at several time points. We observed a clear 
rise in IL-12p40, IP-10, MIG and MIP-1b during the first acute HCV infection. However, 
at the second acute HCV infection there was no increase in biomarkers compared to 
the HIV mono-infected state, before the first acute HCV infection nor after the first 
acute HCV infection had been cured. We hypothesize that the weak pro-inflammatory 
cytokine responses observed during acute HCV re-infection may on the one hand 
further compromise the chances of spontaneous clearance and on the other hand 
may simultaneously prevent damage to the infected organ, the liver(274). One of 
the explanations for these weakened immune response is negative regulation by 
IL-10, TGF-β and regulatory T cells (Tregs). It has been shown that these regulatory 
mechanisms remain active years after therapy-induced eradication of chronic HCV 
infections(275). Possibly, similar processes occur in repeated acute HCV infections.
conclusion and future PersPectiVes
The HCV arena is dynamic and changing very fast. Several new DAAs were successfully 
introduced over the last years and are able to cure the vast majority of patients with 
a chronic HCV infection. Because acute HCV infections are in general more difficult 
to diagnose, the role of DAA based therapy for acute HCV remains to be defined. This 
thesis addresses new treatment and diagnostic opportunities for patients with an 
acute HCV infection in the DAA era. 
In the Netherlands, acute HCV infections are currently diagnosed almost exclusively 
among HIV infected MSM and are mostly sexually transmitted. This epidemic is ongo-
ing and its future course will depend on several factors. The most important factors 
discussed in this thesis are: the adequate use of diagnostic tests, the efficacy, safety 
and availability of DAA treatment, the emergence of viral resistance and the sexual 
behavior of MSM.
One of the most interesting questions in the pegIFN-free era remains whether acute 
HCV infections can be treated with shorter duration regimens than chronic HCV in-
fections. We show in this thesis that a shorter treatment regimen is certainly possible 
when DAAs are added to pegIFN and ribavirin. Studies on the efficacy of DAAs and 
on how DAAs can be used during an acute HCV infection are urgently needed. As 
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we speak, at least two adequately powered prospective studies on the treatment of 
acute HCV are currently enrolling patients, namely the DAHHS-2 (NCT02600325) and 
REACT (NCT02625909).
Whether transmitted drug resistance to DAAs will become clinically relevant is dif-
ficult to predict. The current circulating HCV wild types among acute or chronically 
HCV infected patients do not seem to harbor a lot of clinically relevant resistance. 
Therefore, the large majority of people with acute or chronic HCV can now be cured. 
However, when millions of patients are being treated, a 5% failure rate results in a 
significant number of patients harboring a virus with resistance to at least 1 class 
of DAA. If this is followed by ongoing HCV transmission (as in HIV positive MSM or 
injecting drug users) resistant variants may start to spread. Therefore, despite the 
very high cure rates that we are currently observing, HIV treating physicians should 
be aware of this risk and surveillance is needed. 
We showed that the national reimbursement policy driven by the price of DAAs has a 
huge impact on the epidemic. When immediate DAA treatment is provided to all, the 
most important barrier to elimination of HCV among HIV positive patients will be the 
continued high-risk sexual activity of a subset of HIV positive MSM. The elimination 
of HCV in the Netherlands is just a small step in the eradication of HCV. From a global 
perspective, opiate addiction and inadequate sterilization will remain major risk fac-
tors for ongoing transmission and therefore HCV will probably continue to spread for 
many years. 
The first step in HCV elimination starts with the availability of a cheap and reliable 
test to diagnose a HCV infection. HCV RNA testing remains the gold standard for 
diagnosing acute and chronic HCV infections. However, this method is relatively 
expensive. HCV Ag testing seems to be a promising method, especially in the light of 
frequently testing in high-risk groups. At the moment however, the infrastructure of 
many Dutch hospitals is not ready to implement this test in routine care.
Despite the fact that we have an effective treatment for HCV, many immunological 
issues remain unsolved. In this thesis we study the effects of pegIFN and pegIFN-free 
regimens on MAIT cells. We conclude that MAIT cell frequencies are diminished in vi-
ral infections and do not normalize after effective treatment, regardless of the mode 
of treatment. Additionally, we found differences in biomarker responses between a 
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first and consecutive acute HCV infection. Both studies suggest long-lasting effects 
of a HCV infection even after successful therapy-induced viral eradication. Future 
studies could address this altered state of the immune system and determine to what 
extend this affects patient’s health.  

 Chapter 11
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Infecties met het hepatitis C virus (HCV) komen overal in de wereld in groten ge-
tale voor. HCV zorgt voor een ontsteking van de lever wat een bedreiging is voor 
de gezondheid van de gastheer. In dit proefschrift worden acute HCV infecties 
vanuit verschillende hoeken belicht. Hierbij staat de diagnostiek en behandeling van 
acute HCV infecties bij HIV positieve mannen centraal. Het is niet gemakkelijk een 
exacte definitie van een acute HCV infectie te geven en daardoor is het moeilijk 
om te beoordelen of een patiënt een acute HCV infectie heeft. Binnen verschillende 
medische vakgebieden, bijvoorbeeld virologie, immunologie en bij klinisch onder-
zoek worden wisselende definities gehanteerd. Het is daarom essentieel om goed 
voor ogen te hebben wat een arts, onderzoeker of patiënt bedoelt wanneer deze 
spreekt over een acute HCV infectie. In het algemeen wordt een acute HCV infectie 
gedefinieerd als een nieuwe HCV infectie die binnen de eerste zes maanden na het 
oplopen daarvan wordt gediagnosticeerd. 
De huidige methodes om een acute HCV infectie vast te kunnen stellen hebben 
beperkingen. Daardoor is er behoefte aan onderzoek naar nieuwe diagnostische 
technieken. Daarnaast zorgt de recente opkomst van direct aangrijpende antivirale 
middelen (direct-acting antivirals = DAAs) voor een revolutie in de behandeling 
van chronische (niet-acute) HCV infecties. De effecten en lange termijn gevolgen 
van DAAs voor de behandeling van acute HCV infecties zijn tot op heden minimaal 
bestudeerd en ook daar probeert dit proefschrift een bijdrage aan te leveren. 
In hoofdstuk 1 wordt een uitgebreide inleiding op het ziektebeeld acute HCV infectie 
gegeven en de stand van zaken omtrent acute HCV infecties in de periode tot aan 
dit proefschrift besproken. De huidige epidemie van HCV in Nederland is anders dan 
de epidemie die ontstond in de context van heroïne gebruik in de jaren zeventig en 
tachtig van de vorige eeuw. Momenteel worden de meeste patiënten in Nederland 
besmet via seksueel contact. Het grootste deel van de besmettingen vindt plaats bij 
HIV positieve mannen die seks hebben met mannen (MSM). Bij heteroseksuelen en 
HIV negatieve MSM komt seksuele overdracht van HCV slechts zeer sporadisch voor. 
Het is belangrijk zich te realiseren dat de overdracht van HCV bij MSM een relatief 
kleine groep patiënten betreft. Op globaal niveau wordt HCV echter nog steeds op 
grote schaal verspreid door inadequate sterilisatie van medische instrumenten en 
injecterend drugsgebruik. Kortom, nieuwe HCV infecties komen overal op de wereld 
voor waarbij de overdracht voornamelijk plaatsvindt binnen specifieke risicogroepen. 
De focus van dit proefschrift ligt op HIV positieve MSM met een acute HCV infectie.
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Vanaf hoofdstuk 2 komen de diverse studies die de kern van dit proefschrift vormen 
aan bod. In hoofdstuk 2 wordt het vóórkomen van acute HCV infecties in Nederland 
bestudeerd. In het kader van de Dutch Acute HCV in HIV Study (DAHHS) werd er in 
2014 een meting uitgevoerd waarin aan alle HIV-behandelaren gevraagd werd om 
acute HCV infecties te melden en anonieme karakteristieken van hun patiënten door 
te geven. Uit deze studie blijkt dat er in één jaar tijd 99 nieuwe HCV infecties werden 
gediagnosticeerd onder HIV positieve MSM in de 19 centra die deelnamen aan deze 
incidentiestudie. Het aantal nieuwe infecties wordt daarmee op 11 per 1000 HIV 
positieve MSM per jaar geschat. Dit aantal is vergelijkbaar met de voorspellingen die 
zowel nationaal als internationaal zijn gedaan. Verder concluderen we uit deze studie 
dat een kwart van de patiënten al eerder geïnfecteerd is geweest met HCV en dat er 
dus een aanzienlijke groep is die hoog risico gedrag blijft vertonen. Deze studie toont 
dus aan dat acute HCV infecties binnen HIV positieve MSM, ook in 2014, nog steeds 
frequent voorkomen.
Er zijn verschillende manieren om een acute HCV infectie aan te tonen, maar deze 
hebben beperkingen. De aanwezigheid van viraal genoom in het bloed (RNA) is een 
goede manier om de aanwezigheid van HCV aan te tonen. Hiermee wordt echter geen 
onderscheid gemaakt tussen een langer bestaande en een recente infectie. Om aan 
te tonen dat een infectie acuut is, moet een negatieve HCV test beschikbaar zijn. 
Echter, het aantonen van RNA is relatief duur en de tijd tot het detecteerbaar worden 
van antistoffen (seroconversie) kan tot een jaar duren. Daarom blijft er behoefte aan 
een nieuwe test die goedkoop is en een acute HCV infectie op een gevoelige manier 
kan aantonen. In hoofdstuk 3 presenteren we een studie naar de gevoelige en onder-
scheidende eigenschappen van de HCV antigeen (Ag) test bij het diagnosticeren van 
een acute HCV infectie. Het blijkt dat deze test een goede gevoeligheid (sensitiviteit 
89%) en een goed onderscheidend vermogen heeft (specificiteit 100%) om een 
acute HCV infectie aan te tonen, dan wel uit te sluiten. Dus een HCV Ag bepaling is 
een redelijk alternatief is voor de HCV RNA test. 
Uit onderzoeken bij patiënten met HCV infecties is gebleken dat HCV Ag een rol kan 
hebben in het vervolgen van het effect van een behandeling die gebaseerd is op 
het geven van peginterferon en ribavirine. Deze middelen waren tot 2012 de enige 
middelen die enigszins effectief waren voor de behandeling van HCV. De kans op 
genezing met peginterferon en ribavirine is voor chronische HCV matig maar voor 
een acute HCV hoog. Na de eerste vier weken kan zowel bij acute als chronische HCV 
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op basis van de hoogte van het HCV RNA een inschatting gemaakt worden over de 
kans op genezing na beëindiging van de behandeling. Helaas kunnen we in de studie 
in hoofdstuk 3 niet aantonen dat HCV Ag deze HCV RNA metingen om effect van 
therapie te vervolgen goed kan vervangen.
In hoofdstuk 4 komt de DAHH-Studie aan bod. In deze studie zijn patiënten met 
een acute HCV behandeld met peginterferon, ribavirine en boceprevir. Boceprevir is 
één van de eerste DAAs die in combinatie met peginterferon en ribavirine voor de 
behandeling van chronische HCV kon worden gebruikt. Omdat er destijds nog geen 
onderzoek was verricht naar de effectiviteit van boceprevir bij de behandeling van 
acute HCV, is de DAHH-Studie opgezet. In deze studie wordt het behandelschema 
van een acute HCV infectie verkort van standaard 24 naar 12 weken. Deze kortere 
behandeling met drie geneesmiddelen leidt tot een genezingspercentage van 100% 
binnen de groep patiënten die op week 4 van behandeling al geen aantoonbaar HCV 
RNA meer heeft. In de totale groep behandelde patiënten is 86% van de patiënten 
genezen. Binnen de studie vergelijken we deze resultaten met de reguliere behan-
deling van 24 weken peginterferon met ribavirine. Het genezingspercentage in deze 
controle groep is 84%. Dus we concluderen dat door het toevoegen van een extra 
middel de behandelduur van een acute HCV infectie gehalveerd kan worden. Omdat 
peginterferon en ribavirine een aantal ernstige bijwerkingen hebben is deze verkort-
ing een belangrijke winst. 
De combinatie van HIV-remmers en andere medicatie kan voor interacties zorgen die 
nadelig zijn voor een patiënt. De combinatie van boceprevir en rilpivirine, een hiv 
remmer, kan tot een extra stijging van de rilpivirine spiegel in het bloed leiden. Om-
dat hoge rilpivirine spiegels theoretisch kunnen resulteren in hartritmestoornissen, 
onderzochten wij het effect van boceprevir op de rilpivirine spiegel. In hoofdstuk 
5 laten we zien dat boceprevir daadwerkelijk voor hogere rilpivirine spiegels zorgt, 
maar dat het electrocardiogram, waarop een afwijking een voorbode kan zijn van 
hartritmestoornissen, normaal blijft.
DAAs zijn nieuwe middelen voor de behandeling van HCV. Het gebruik van deze 
middelen leidt over het algemeen tot hele hoge genezingspercentages omdat ze de 
virusproductie op een heel krachtige manier remmen. Deze remming vindt daarbij, in 
tegenstelling tot peginterferon, heel selectief plaats waardoor er weinig bijwerkingen 
zijn. Door de populariteit van deze middelen wordt er gezegd dat HCV een ziekte is 
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die theoretisch volledig geëlimineerd kan worden. In hoofdstuk 6 wordt een model-
leringsstudie gepresenteerd waarin effecten worden getoond van verschillende 
behandelstrategieën van HCV op landelijk niveau. In deze studie vergelijken we het 
direct behandelen van alle HCV/HIV positieve MSM met deze DAAs met het uitstel-
len van behandeling totdat er ernstige leverschade wordt vastgesteld. Wachten 
op het ontstaan van ernstige leverschade is in theorie mogelijk omdat HCV maar 
bij een beperkt deel van de HIV positieve patiënten (ongeveer 30%) binnen een 
termijn van 30 jaar ernstige leverschade ontstaat. Dus zolang er geen leverschade 
ontstaat hebben de meeste patiënten niet direct baat bij een behandeling. Een 
andere belangrijke reden om te wachten met therapie is de, op dit moment, zeer 
hoge prijs van DAAs. Wachten met de behandeling kan op populatieniveau echter 
ook negatieve gevolgen hebben. Zolang een patiënt een HCV infectie heeft, kan hij 
deze namelijk ook overdragen. Daarom zou het toch zinvol en doelmatig kunnen zijn 
om alle patiënten met een nieuwe HCV infectie direct te behandelen. In hoofdstuk 
6 laten we zien dat het direct behandelen van alle patiënten een flinke daling in het 
totale aantal patiënten met HCV en ook in het aantal nieuwe geïnfecteerde patiënten 
geeft. Echter, in de studie concluderen wij ook dat het niet lukt om HCV binnen de 
HIV positieve patiënten volledig te elimineren. Als behandelingen worden uitgesteld 
tot gevorderde leverschade, zal de epidemie zelfs in omvang toenemen. Naast het 
effect op de epidemie zijn er ook effecten op de kosten en baten van deze andere 
behandelstrategie. Als de kosten op de lange termijn worden afgezet tegen de baten, 
dan lijkt het direct behandelen van alle patiënten kosteneffectief. Als de prijs van 
een behandeling met DAAs van 40.000 euro per behandeling naar 20.000 euro per 
behandeling zou gaan dan zou dat zelfs resulteren in een kostenbesparing. Kortom, 
het direct behandelen van alle patiënten met HIV en HCV lijkt een zinvolle invester-
ing op landelijk niveau.
Ondanks de zeer hoge genezingskans na behandeling met DAAs, kan het HCV wel 
ongevoelig voor deze middelen worden. Dit wordt resistentie genoemd en berust 
op het ontstaan van kleine veranderingen in het genoom (mutaties). In hoofdstuk 7 
onderzoeken we de aanwezigheid van resistentie in het virale genoom bij de DAHHS 
patiënten. Omdat de patiënten van de DAHH-Studie geïnfecteerd werden in 2013 en 
2014, liepen deze het risico om geïnfecteerd te zijn met een virus dat al resistentie 
had verworven tegen boceprevir of telaprevir. Beide middelen, die dezelfde werk-
ing hebben, werden namelijk vanaf 2012 gebruikt en bij een aanzienlijk deel van 
de patiënten mislukte deze behandeling. De kans dat het HCV van deze patiënten 
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bij wie de behandeling mislukte resistent werd voor deze DAAs is groot. Als deze 
patiënten vervolgens het virus overdragen, kan het resistente virus zich verspreiden. 
Als dit op grote schaal gebeurt dan kan dat effect hebben op de effectiviteit van 
DAAs. In de studie in hoofdstuk 7 vinden we op het moment dat de patiënten starten 
met hun HCV behandeling geen mutaties die met zekerheid door eerdere therapie 
met boceprevir of telaprevir veroorzaakt is. Wel vinden we bepaalde variaties in het 
virale genoom in de DAHHS populatie (bijvoorbeeld Q80K in NS3/4a). Deze kunnen 
van nature voorkomen maar zijn wel in verband gebracht met significante resistentie 
tegen nieuwere DAAs. Ondanks het feit dat wij geen overgedragen resistentie vinden, 
blijft het mogelijk dat dit in de toekomst een probleem wordt. Er zijn namelijk nog 
steeds groepen waarin DAAs niet optimaal werken of niet optimaal gebruikt worden. 
Als in deze groepen, na falen van de behandeling, resistentie van HCV tegen deze 
DAAs ontstaat, zou dit overgedragen kunnen worden. Dus behandelaren moeten ook 
in de toekomst waakzaam zijn voor het ontstaan van resistente varianten. 
Als laatst worden er in hoofdstuk 8 en 9 twee studies gepresenteerd die het im-
munologisch profiel van een acute HCV infectie bestuderen. In het verleden zijn er 
duidelijke verschillen aangetoond in de immuunrespons tussen acuut en chronisch 
geïnfecteerde patiënten. Echter, in de kliniek hebben deze bevindingen nog geen 
diagnostische waarde. Bij patiënten met een chronische HCV infectie wordt een soort 
uitgeputte immuunrespons geobserveerd, waardoor het immuunsysteem niet meer 
in staat is krachtig te reageren zoals tijdens de acute fase. In hoofdstuk 8 wordt de 
mucosal invariant T (MAIT) cel bestudeerd. Dit is een afweer (T) cel die waarschijnlijk 
een rol speelt bij de bacteriële afweer. Aangezien patiënten met HIV en HCV vaker 
bacteriële infecties hebben en de mate van aanwezigheid van deze cel in verband is 
gebracht met leverschade (fibrose) in eerder onderzoek, waren we geïnteresseerd in 
het functioneren van deze cellen. We observeren in deze studie lagere frequenties 
van MAIT cellen binnen de totale T cel populatie bij zowel HIV, chronische HCV als 
acute HCV/HIV co-infecties ten opzichte van gezonde controles. Na succesvolle be-
handeling van de HCV infectie lijkt er geen herstel te zijn van deze frequenties. Ook 
lijken er wat betreft MAIT cellen weinig verschillen te zijn tussen acute en chronische 
HCV infecties. Het enige aantoonbare onderscheid dat we vaststellen tussen acute 
en chronische HCV is een toegenomen aantal activatiemarkers op MAIT cellen bij 
acute HCV. Deze verhoogde staat van activatie vertaalt zich in deze studie echter niet 
in een verhoogde productie van interferon. 
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In hoofdstuk 9 wordt een studie gepresenteerd waarin het biomarker profiel van 
acute HCV infecties en HCV herinfecties wordt onderzocht en vergeleken. Biomarkers 
zijn in deze studie gedefinieerd als stoffen die door cellen worden geproduceerd om 
een ontstekingsreactie op gang te brengen of juist tegen te gaan. Het doel van deze 
studie is om te onderzoeken of tijdens een eerste en een daaropvolgende infectie 
met HCV dezelfde veranderingen van het immuunsysteem optreden. Dit is dus een 
infectie met een nieuw HCV nadat de voorgaande infectie genezen is. Hiervoor zijn 
acht biomarkers geselecteerd en op meerdere momenten tijdens opeenvolgende 
infecties getest. In eerste instantie onderzoeken we of biomarkers veranderen bij 
HIV positieve patiënten op het moment dat ze een eerste acute HCV infectie krijgen. 
Vervolgens zijn dezelfde biomarkers opnieuw bepaald gedurende de tweede acute 
HCV infectie. Van een aantal biomarkers kunnen we aantonen dat deze significant 
toenemen gedurende de eerste HCV infectie. Echter, bij de tweede HCV infectie 
zien we deze toename niet duidelijk. Een goede verklaring hebben we hier niet voor 
kunnen vinden. Mogelijk zijn er na een eerste infectie langdurige verandering in het 
immuunsysteem opgetreden die een reactie op een nieuwe infectie anders maken. 
conclusie
Een acute HCV infectie is een zeldzaam ziektebeeld dat in Nederland voornamelijk 
wordt gediagnosticeerd bij HIV positieve MSM. Bij deze mannen wordt het virus 
seksueel overgedragen. Het is soms lastig te beoordelen of een HCV infectie in de 
afgelopen zes maanden is opgelopen en daarmee als acuut kan worden gedefinieerd. 
Het verschil tussen een acute en chronische HCV infectie is zichtbaar wanneer in 
detail naar de immunologische respons wordt gekeken. Ook is een behandeling 
met peginterferon veel effectiever tijdens een acute infectie. De beschikbaarheid 
van DAAs creëert nieuwe behandelopties voor patiënten met acute HCV infecties. 
In dit proefschrift tonen we aan dat de toevoeging van boceprevir aan peginterferon 
en ribavirine de behandeling van acute HCV infecties kan verkorten van 24 naar 12 
weken zonder verlies van effectiviteit. Echter, de toekomstige behandeling van acute 
HCV zal waarschijnlijk uit een combinatie van DAAs zonder peginterferon bestaan. 
Indien alle acute HCV infecties hiermee direct na diagnose behandeld kunnen wor-
den dan zal dit waarschijnlijk leiden tot een belangrijke afname van de epidemie in 
Nederland. Het ontstaan van resistentie tegen DAAs lijkt op dit moment nog geen 
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groot probleem maar waakzaamheid is nodig nu de DAA behandeling in Nederland 
breed wordt toegepast.
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DAHHS-1 
DAHHS-2
Attended meetings/conferences 
PhD day Erasmus MC 2015
Gilead 1216 investigators 2015
Merck 1439a investigators 2015
5th workshop on HCV therapy 2015
CPO Erasmus MC 2014
PhD day Erasmus MC 2014
7th Dutch conference on HIV 2013
About the Author 205
14
curriculum Vitae
Sebastiaan Hullegie was born on February 27th 1988 in Gouda, the Netherlands. In 
2006 he graduated from the Marnix College in Ede and started his medical training 
at the Erasmus MC University Medical Center. After his second year, he was during 
one year a full time member of the student society board of the Erasmus MC Univer-
sity Medical Center. Afterwards he was chairman of the student faculty counsel and 
founded the ‘Erasmus Journal of Medicine’: a journal that provides a forum for young 
investigators to publish their first research. In 2013, his graduation research focused 
on hospital acquired infections after surgery. After obtaining his medical degree he 
started as a PhD candidate under supervision of prof. dr. Verbon and dr. Rijnders at 
the Erasmus MC University Medical Center.

